CN108148863A - 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 - Google Patents
一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 Download PDFInfo
- Publication number
- CN108148863A CN108148863A CN201611103319.2A CN201611103319A CN108148863A CN 108148863 A CN108148863 A CN 108148863A CN 201611103319 A CN201611103319 A CN 201611103319A CN 108148863 A CN108148863 A CN 108148863A
- Authority
- CN
- China
- Prior art keywords
- seq
- slow virus
- car
- cell
- lvcar19
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 title claims abstract description 42
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 title claims abstract description 33
- 108700019146 Transgenes Proteins 0.000 title claims abstract description 15
- 239000000969 carrier Substances 0.000 title claims abstract description 15
- 238000010276 construction Methods 0.000 title claims abstract description 15
- 241000700605 Viruses Species 0.000 claims abstract description 104
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 57
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 30
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 27
- 238000004806 packaging method and process Methods 0.000 claims abstract description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 13
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract description 11
- 230000027455 binding Effects 0.000 claims abstract description 11
- 238000009739 binding Methods 0.000 claims abstract description 11
- 229940116886 human interleukin-6 Drugs 0.000 claims abstract description 11
- 230000005540 biological transmission Effects 0.000 claims abstract description 8
- 230000003612 virological effect Effects 0.000 claims abstract description 8
- 241000555745 Sciuridae Species 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims abstract description 5
- 229960000723 ampicillin Drugs 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 230000001124 posttranscriptional effect Effects 0.000 claims abstract description 5
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 97
- 239000013612 plasmid Substances 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 36
- 241000713666 Lentivirus Species 0.000 claims description 35
- 102000005962 receptors Human genes 0.000 claims description 35
- 108020003175 receptors Proteins 0.000 claims description 35
- 239000013598 vector Substances 0.000 claims description 35
- 230000029087 digestion Effects 0.000 claims description 30
- 239000006228 supernatant Substances 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 26
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 25
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 15
- 230000035897 transcription Effects 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 230000002103 transcriptional effect Effects 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 10
- 238000013461 design Methods 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 7
- 230000006044 T cell activation Effects 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims description 3
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 230000006052 T cell proliferation Effects 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 238000001994 activation Methods 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 230000030833 cell death Effects 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 238000005336 cracking Methods 0.000 claims description 2
- 230000007783 downstream signaling Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 210000003705 ribosome Anatomy 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 125
- 108020004414 DNA Proteins 0.000 description 95
- 239000000047 product Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 32
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 28
- 238000000246 agarose gel electrophoresis Methods 0.000 description 24
- 239000000499 gel Substances 0.000 description 23
- 206010052015 cytokine release syndrome Diseases 0.000 description 21
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 description 18
- 238000010586 diagram Methods 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 18
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 229910001868 water Inorganic materials 0.000 description 16
- 238000001514 detection method Methods 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 238000001962 electrophoresis Methods 0.000 description 14
- 239000003550 marker Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000204031 Mycoplasma Species 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 241000030538 Thecla Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 101150058049 car gene Proteins 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000018511 hepcidin Human genes 0.000 description 1
- 108060003558 hepcidin Proteins 0.000 description 1
- 229940066919 hepcidin Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010010 raising Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00041—Use of virus, viral particle or viral elements as a vector
- C12N2760/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Abstract
本发明公开了一种封闭IL6R的用于缓解CRS的CAR‑T转基因载体,包括:含氨苄青霉素抗性基因AmpR序列(SEQ ID NO.1);原核复制子pUC Ori序列(SEQ ID NO.2);病毒复制子SV40 Ori序列(SEQ ID NO.3);eWPRE增强型土拨鼠乙肝病毒转录后调控元件(SEQ ID NO.11);人EF1α启动子(SEQ ID NO.12);用于慢病毒包装的慢病毒包装顺式元件;人IL6R的人源化单链抗体IL6RscFv1(SEQ ID NO.21)、IL6RscFv2(SEQ ID NO.22)、或IL6RscFv3(SEQ ID NO.23);IRES核糖体结合序列(SEQ ID NO.25);IL6信号肽(SEQ ID NO.26);人源抗体Fc段(SEQ ID NO.27);以及用于组成集识别、传递、启动于一体的二代CAR或三代CAR的嵌合抗原受体。此外,本发明还公开了该载体的构建方法及其在制备缓解CRS的药物中的应用。
Description
技术领域
本发明属于医学生物领域,具体涉及一种载体,尤其涉及一种封闭IL6R的用于缓解CRS的CAR-T转基因载体。此外,本发明还涉及该载体的构建方法和应用。
背景技术
肿瘤免疫治疗的理论基础是免疫系统具有识别肿瘤相关抗原、调控机体攻击肿瘤细胞(高度特异性的细胞溶解)的能力。1950年代,Burnet和Thomas提出了“免疫监视”理论,认为机体中经常会出现的突变的肿瘤细胞可被免疫系统所识别而清除,为肿瘤免疫治疗奠定了理论基础[Burnet FM.Immunological aspects of malignant disease.Lancet,1967;1:1171-4]。随后,各种肿瘤免疫疗法包括细胞因子疗法、单克隆抗体疗法、过继免疫疗法、疫苗疗法等相继应用于临床。
2013年一种更先进的肿瘤免疫疗法---CAR-T疗法成功用于临床,并表现了前所未有的临床疗效。CAR-T,全称是Chimeric Antigen Receptor T-Cell Immunotherapy,嵌合抗原受体T细胞免疫疗法。CAR-T疗法在临床上最领先的有诺华的CLT019,采用CLT019治疗复发难治急性淋巴细胞白血病患者,六个月的肿瘤无进展生存率达到67%,其中最长的应答时间达到两年多。总部位于中国上海的上海优卡迪生物医药科技有限公司与医院合作,共治疗复发难治急性淋巴细胞白血病患者36例,其中完全24例,缓解比例达到66.6%。这是抗癌研究的颠覆性突破。CAR-T细胞疗法可能是最有可能治愈癌症的手段之一,并被《Science》杂志评为2013年度十大科技突破之首。
CAR-T疗法虽然效果显著,但是在治疗过程中会出现一类特殊的临床综合症,临床常表现为发热,低血压,寒颤,以及出现与血清中一系列细胞因子水平显着升高有关的神经系统症状,被称为细胞因子释放综合症(Cytokine Release Syndrome,CRS)。其发生机制是由于抗原与T细胞受体结合后,激活了T细胞,T细胞被激活后释放了包括IL-6在内的一系列细胞因子,造成了一种系统性的炎症反应,IL-6信号通路如图1A所示。如果治疗不及时,会导致一系列的症状包括肺部感染、凝血指标不正常、肝功能不正常、重要器官损害,甚至很引起肺水肿而导致患者死亡。
目前临床上可通过静脉注射抗组胺类药物(如扑尔敏)或皮质类固醇(如氢化可的松)来抑制炎症反应,但是相应的,CAR-T细胞对肿瘤的杀伤作用也被抑制,使得这类患者,有较高的复发率,影响CAR-T治疗的疗效。
还有一个比较可行的方案是使用商品化的托珠单抗(雅美罗)来控制CRS的发生程度。托珠单抗是一种人源化的IL-6受体单克隆抗体(Tocilizumab),托珠单抗与IL-6受体发生特异性结合,阻断IL-6信号转导,从而减少急性时相反应物、降低铁调素产物、减少B细胞活化、减少骨吸收和软骨转化,以及抑制T淋巴细胞向Th17细胞的分化,从而有效控制炎症反应。但是使用托珠单抗的费用很高,一支10kg体重剂量的托珠单抗价格约为2000元RMB,成年患者一般一次要用5支,普通家庭难以承受。
因此,如何采用低成本的方法来控制或缓解CRS的发生,并且不影响CAR-T治疗的疗效,成为了本领域的一个技术难题。
发明内容
本发明要解决的技术问题之一是提供一种封闭IL6R的用于缓解CRS的CAR-T转基因载体。首先,其节约了成本,省去了购买抗体药物的昂贵费用。其次,避免了scFv基因的在体递送效率低的问题。第三,通过慢病毒转导的IL6R scFv基因,能够有效利用细胞内的蛋白质翻译体系,大量表达出相应的IL6R scFv,经过体液循环,达到良好的IL6R封闭效果,不影响CAR-T治疗的疗效。
本发明要解决的技术问题之二是提供该载体的构建方法。
本发明要解决的技术问题之三是提供该载体的应用。
为解决上述技术问题,本发明采用如下技术方案:
在本发明的一方面,提供一种封闭IL6R的用于缓解CRS的CAR-T转基因载体,包括:
用于目的菌株大量扩增的含氨苄青霉素抗性基因AmpR序列,如SEQ ID NO.1所示;
用于质粒复制的原核复制子pUC Ori序列,如SEQ ID NO.2所示;
用于增强真核细胞内的复制的病毒复制子SV40Ori序列,如SEQ ID NO.3所示;
用于增强转基因的表达效率的eWPRE增强型土拨鼠乙肝病毒转录后调控元件,如SEQ ID NO.11所示;
用于嵌合抗原受体基因的真核转录的人EF1α启动子,如SEQ ID NO.12所示;
用于慢病毒包装的慢病毒包装顺式元件;
人IL6R的人源化单链抗体,所述人IL6R的人源化单链抗体为如SEQ ID NO.21所示的IL6RscFv1,或者如SEQ ID NO.22所示的IL6RscFv2,或者如SEQ ID NO.23所示的IL6RscFv3;
用于共同转录表达蛋白质的IRES核糖体结合序列,如SEQ ID NO.25所示;
IL6信号肽,如SEQ ID NO.26所示;
人源抗体Fc段,如SEQ ID NO.27所示;
以及用于组成集识别、传递、启动于一体的二代CAR或三代CAR的嵌合抗原受体。
作为本发明优选的技术方案,所述人IL6R的人源化单链抗体为如SEQ ID NO.21所示的IL6RscFv1。
所述慢病毒包装顺式元件可以采用第二代慢病毒载体或者第三代慢病毒载体,优选第三代慢病毒载体。所述第二代慢病毒载体包括:如SEQ ID NO.5所示的慢病毒5terminal LTR、如SEQ ID NO.6所示的慢病毒3terminal Self-Inactivating LTR、如SEQID NO.7所示的Gag顺式元件、如SEQ ID NO.8所示的RRE顺式元件、如SEQ ID NO.9所示的env顺式元件、如SEQ ID NO.10所示的cPPT顺式元件。所述第三代慢病毒载体包括:如SEQID NO.5所示的慢病毒5terminal LTR、如SEQ ID NO.6所示的慢病毒3terminal Self-Inactivating LTR、如SEQ ID NO.7所示的Gag顺式元件、如SEQ ID NO.8所示的RRE顺式元件、如SEQ ID NO.9所示的env顺式元件、如SEQ ID NO.10所示的cPPT顺式元件,以及如SEQID NO.4所示的RSV启动子。
作为本发明优选的技术方案,所述用于组成集识别、传递、启动于一体的二代CAR的嵌合抗原受体包括:如SEQ ID NO.13所示的CD8leader嵌合受体信号肽、如SEQ ID NO.14所示的CD19单链抗体轻链VL、如SEQ ID NO.15所示的Optimal Linker C、如SEQ ID NO.16所示的CD19单链抗体重链VH、如SEQ ID NO.17所示的CD8Hinge嵌合受体铰链、如SEQ IDNO.18所示的CD8Transmembrane嵌合受体跨膜区、如SEQ ID NO.19所示的CD137嵌合受体共刺激因子、如SEQ ID NO.20所示的TCR嵌合受体T细胞激活域;所述用于组成集识别、传递、启动于一体的三代CAR的嵌合抗原受体包括:如SEQ ID NO.13所示的CD8leader嵌合受体信号肽、如SEQ ID NO.14所示的CD19单链抗体轻链VL、如SEQ ID NO.15所示的OptimalLinker C、如SEQ ID NO.16所示的CD19单链抗体重链VH、如SEQ ID NO.17所示的CD8Hinge嵌合受体铰链、如SEQ ID NO.18所示的CD8Transmembrane嵌合受体跨膜区、如SEQ IDNO.19所示的CD137嵌合受体共刺激因子、如SEQ ID NO.20所示的TCR嵌合受体T细胞激活域、以及如SEQ ID NO.28所示的CD28嵌合受体共刺激因子。
作为本发明优选的技术方案,所述eWPRE增强型土拨鼠乙肝病毒转录后调控元件有6个核苷酸的增强突变,具体为:g.396G>A、g.397C>T、g.398T>C、g.399G>A、g.400A>T、g.411A>T。
在本发明的第二方面,提供一种上述封闭IL6R的用于缓解CRS的CAR-T转基因载体的构建方法,包括以下步骤:
(1)将如SEQ ID NO.1所示的含氨苄青霉素抗性基因AmpR序列、如SEQ ID NO.2所示的原核复制子pUC Ori序列、如SEQ ID NO.3所示的病毒复制子SV40Ori序列、用于慢病毒包装的慢病毒包装顺式元件、如SEQ ID NO.11所示的eWPRE增强型土拨鼠乙肝病毒转录后调控元件存储于慢病毒骨架质粒上;
(2)将如SEQ ID NO.12所示的人EF1α启动子、用于组成集识别、传递、启动于一体的二代CAR或三代CAR的嵌合抗原受体组合成二代CAR或三代CAR设计方案,经过酶切、连接、重组反应克隆至慢病毒骨架质粒中,得到二代CAR或三代CAR设计的重组慢病毒质粒;
(3)将人IL6R的人源化单链抗体IL6RscFv1、IL6RscFv2、或IL6RscFv3,IRES核糖体结合序列、IL6信号肽以及人源抗体Fc段分别克隆至重组慢病毒质粒中,得到IL-6R阻断重组慢病毒质粒pCAR19-IL6RscFv1、pCAR19-IL6RscFv2、或pCAR19-IL6RscFv3;
(4)将得到的重组慢病毒质粒pCAR19-IL6RscFv1、pCAR19-IL6RscFv2、或pCAR19-IL6RscFv3分别与慢病毒包装质粒pPac-GP、pPac-R以及膜蛋白质粒pEnv-G共同转染HEK293T/17细胞,在HEK293T/17细胞中进行基因转录表达后,包装成功重组慢病毒载体会释放到细胞培养上清中,收集包含的重组慢病毒载体的上清液;
(5)将得到的重组慢病毒上清采用抽滤、吸附、洗脱的柱纯化方式进行纯化,分别得到重组慢病毒载体。
作为本发明优选的技术方案,步骤(3)中,由人EF1α启动子启动整个CAR基因表达;CAR蛋白定位于细胞膜表面,识别CD19抗原,刺激T细胞增殖和细胞因子分泌,激活下游信号通路的表达;当scfv区域与CD19抗原结合时,信号通过嵌合受体传递至细胞内,从而产生T细胞增殖、细胞因子分泌增加、抗细胞凋亡蛋白分泌增加、细胞死亡延迟、裂解靶细胞一系列生物学效应;由IRES核糖体结合序列共表达IL6RscFv与Fc的融合蛋白,并在IL6信号肽的引导下分泌到细胞外,通过与IL6R的结合,阻断IL-6的与IL6R的结合,从而阻断IL6的信号通路,达到抑制CRS的效果。
作为本发明优选的技术方案,步骤(5)中,所述抽滤步骤要控制上清体积在200ml~2000ml,控制真空度在-0.5MPA~-0.9MPA,防止由于堵孔带来的载体损失;所述吸附步骤要控制溶液的PH值在6~8,防止PH的变化导致载体失活;所述洗脱步骤要控制洗脱液的离子强度在0.5M~1.0M,防止离子强度的变化导致洗脱不完全或者载体失活。
在本发明的第三方面,提供上述载体在制备缓解CRS的药物中的应用。
与现有技术相比,本发明具有如下有益效果:
本发明是将IL6信号肽、人IL6R的单链抗体、IRES核糖体结合序列、人源抗体Fc段、人EF1α启动子、CD8leader嵌合受体信号肽、CD19单链抗体轻链VL、Optimal Linker C、CD19单链抗体重链VH、CD8Hinge嵌合受体铰链、CD8Transmembrane嵌合受体跨膜区、CD137嵌合受体共刺激因子、TCR嵌合受体T细胞激活域构建进入重组慢病毒载体,由人EF1α启动子启动整个CAR基因表达。CAR蛋白定位于细胞膜表面,识别CD19抗原,刺激T细胞增殖和细胞因子分泌,激活下游信号通路的表达。当scfv区域与CD19抗原结合时,信号通过嵌合受体传递至细胞内,从而产生T细胞增殖、细胞因子分泌增加、抗细胞凋亡蛋白分泌增加、细胞死亡延迟、裂解靶细胞等一系列生物学效应。由IRES核糖体结合序列共表达IL6RscFv与Fc的融合蛋白,并在IL6信号肽的引导下分泌到细胞外,通过与IL6R的结合,阻断IL-6的与IL6R的结合,从而阻断IL6的信号通路,达到抑制CRS的效果。
本发明所采用的IL6R的阻断方案,可以应用于第二代或第三代CAR设计方案。第三代CAR设计与第二代设计相比,增加了CD28嵌合受体共刺激因子(SEQ ID NO.28),文献报道会有更强的信号放大作用[Eleanor J.Cheadle,et al.CAR T cells:driving the roadfrom the laboratory to the clinic.Immunological Reviews 2014.Vol.257:91–106]。
本发明所采用的慢病毒载体柱纯化系统(如图7所示),系本申请人开发出的慢病毒规模化生产工艺(已在2016年3月17日申请的“一种基于复制缺陷性重组慢病毒的CAR-T转基因载体及其构建方法和应用”发明专利中公开)。常用的超速离心法或者高速离心法,是利用离心沉降原理分离慢病毒颗粒,不可避免的会残留很多沉降系数相近的杂质,对后续实验带来不利影响。并且,装管过程复杂、操作繁琐、多次转换容器带来更多的污染机会。而本公司开发的慢病毒载体柱纯化工艺为半自动化操作,全部过程在百级实验区域完成,避免人工操作的繁琐、失误和污染几率,所回收的慢病毒载体在内毒素、支原体、宿主DNA残留等指标上完全达到临床标准。后续可跟进开发全自动纯化仪。
本发明所采用CAR设计方案也可以应用于第二代慢病毒载体结构上(已在2016年3月17日申请的“一种基于复制缺陷性重组慢病毒的CAR-T转基因载体及其构建方法和应用”发明专利中公开)。第二代和第三代慢病毒载体在结构上的区别(如图2B所示),主要是第三代慢病毒载体把第二代载体5’LTR的U3区域替换为RSV启动子,这样就消除了U3转录时对Tat蛋白的依赖,既可以在慢病毒的结构基因里去除Tat序列,也提高了慢病毒基因组转录水平和转录持续性。第二代和第三代慢病毒载体主要是基因组转录方式的区别,因此本发明所采用CAR设计方案可以应用于这两代慢病毒载体。本发明所采用的载体骨架优选为第三代慢病毒载体(如图2A所示)(已在2016年3月17日申请的“一种基于复制缺陷性重组慢病毒的CAR-T转基因载体及其构建方法和应用”发明专利中公开),3’SIN LTR去除了U3区域,消除了慢病毒载体自我复制的可能性,大大提高了安全性;增加了cPPT和WPRE元件,提高了转导效率和转基因的表达效率;采用RSV启动子保证了慢病毒载体包装时核心RNA的持续高效转录;采用人自身的EF1α启动子,使CAR基因能够在人体内长时间持续表达。
由本申请人开发的第三代慢病毒骨架质粒(已在2016年3月17日申请的“一种基于复制缺陷性重组慢病毒的CAR-T转基因载体及其构建方法和应用”发明专利中公开),采用enhancedWPRE元件,与宾州大学Carl H.June等人(Porter DL,Levine BL,Kalos M,BaggA,June CH.Chimeric antigen receptormodified T cells in chronic lymphoidleukemia.N Engl J Med 2011;365:725-33.)所采用的WPRE元件相比,有6个核苷酸的增强突变(g.396G>A、g.397C>T、g.398T>C、g.399G>A、g.400A>T、g.411A>T),能够增强初级转录产物的多聚腺苷化,增加细胞内mRNA的含量,增强转基因的表达效率。
本申请采用的Lentival包装系统是无辅助病毒的四质粒包装系统(已在2016年3月17日申请的“一种基于复制缺陷性重组慢病毒的CAR-T转基因载体及其构建方法和应用”发明专利中公开),通过四种质粒共同转染至HEK293T/17细胞中,产生重组慢病毒载体。重组后的慢病毒载体是复制缺陷型载体,能将外源片段整合入宿主基因,一次性使用,无法复制和增殖,安全性有很大提高。
本发明所采用的是针对IL-6R的单链抗体封闭技术,单链抗体(single chainantibody fragment,scFv),是由抗体重链可变区和轻链可变区通过15~20个氨基酸的短肽(linker)连接而成。scFv能较好地保留其对抗原的亲和活性,并具有分子量小、穿透力强和抗原性弱等特点。本发明所采用的人IL6R阻断单链抗体设计,能够有效在T细胞中过表达并分泌至胞外,能够有效阻断IL-6与IL6R结合,阻断IL6信号通路的激活,在T细胞杀伤实验中,经过QPCR检测,能有效抑制PBMC中C-reactive protein的mRNA的转录水平,降低细胞培养上清中的C-reactive protein蛋白含量,经IL-6R阻断效果评估实验证明,本发明载体可以在体内抑制IL-6信号通路,减轻并缓解CRS的症状。
本发明中采用的scFv片段和抗体Fc段,均经过人源化改造,能有效减少体内人抗鼠抗体(Human anti-mouse antibodies,HAMA)的产生,提高scFv的半衰期和作用效果。
本发明采用的scfv段的Linker设计(已在2016年3月17日申请的“一种基于复制缺陷性重组慢病毒的CAR-T转基因载体及其构建方法和应用”发明专利中公开),能够显著提高细胞因子的分泌、CAR-T细胞的体外杀伤作用以及临床治疗效果。
本发明采用IL6R scFv的作用方式(如图1B所示)。首先,节约了成本,省去了购买抗体药物的昂贵费用。其次,避免了scFv基因的在体递送效率低的问题。第三,通过慢病毒转导的IL6R scFv基因,能够有效利用细胞内的蛋白质翻译体系,大量表达出相应的IL6RscFv,经过体液循环,达到良好的IL6R封闭效果。本发明筛选了一系列IL6R抗体的基因序列、氨基酸序列等生物信息学方面的信息,预测了IL6R scFv的重链及轻链的可变区,分析了IL6R scFv组合的二级结构及其物理化学性质,通过可溶性表达和间接ELISA法测定了IL6R scFv的亲和力常数,从中优选出3条scFv进行细胞功能水平的检测,最终确定了IL6RscFv1作为最佳选择,未来可进入临床研究阶段。本发明的重组慢病毒载体骨架可以搭载不同的治疗性基因并广泛地用于过继性细胞治疗领域,搭载IL6R scFv基因用于封闭IL6R。本发明的重组慢病毒载体可以实现在人T淋巴细胞上表达CD19嵌合抗原受体,引导并激活T淋巴细胞对CD19阳性细胞的杀伤作用,在临床上用于治疗B淋巴细胞白血病、B淋巴瘤和多发性骨髓瘤。在人T淋巴细胞内表达白介素-6受体(IL-6R)的scFv,有效封闭IL6R,阻断IL-6信号通路,临床上可用于缓解细胞因子释放综合症CRS。可见,本发明采用低成本的方法来控制或缓解CRS的发生,并且不影响CAR-T治疗的疗效,解决了本领域的技术难题,且达到了预料不到的技术效果。
本发明所述的IL-6R单链抗体表达框及其基因表达产物,不仅可以应用于CAR19-T(CD19-CAR-T)治疗急性B淋巴细胞白血病(ALL)中用于消除或减轻CRS的症状,还可应用于缓解CAR-T治疗诸如胰腺癌、脑胶质瘤、骨髓瘤等等所有类型肿瘤时引起的CRS症状,甚至还可以应用于缓解其他类型的治疗引起的CRS。
附图说明
图1A是本发明的IL-6信号通路示意图。
图1B是本发明的IL6R scFv的作用方式示意图;
图2是本发明的慢病毒载体结构示意图;其中图2A是本发明采用的第三代慢病毒载体结构示意图,图2B是第二代和第三代慢病毒载体结构比较示意图;
图3为本发明实施例1中构建本发明所述的重组慢病毒载体的构建流程图。其中,(A)图是慢病毒骨架质粒pLenti-3G Basic2的结构示意图;(B)图是pCAR19-Basic2质粒的结构示意图;(C)图是pCAR19-IL6RscFv1、pCAR19-IL6RscFv2、pCAR19-IL6RscFv3、pCAR19-scFv0质粒的示意图;(D)图是慢病毒包装质粒pPac-GP的结构示意图;(E)图是慢病毒包装质粒pPac-R的结构示意图;(F)图是膜蛋白pEnv-G的结构示意图;
图4是本发明实施例1中慢病毒骨架质粒pLenti-3G Basic2的酶切预测及酶切琼脂糖凝胶电泳图;图4A是慢病毒骨架质粒pLenti-3G Basic2的酶切预测示意图,其中,lane1是pLenti-3G Basic2的Cla I+BamH I酶切预测,条带从上到下依次为:5854bp;lane 2是1kb DNA ladder Marker预测,条带从上到下依次为:10kb、8kb、6kb、5kb、4kb、3.5kb、3kb、2.5kb、2kb、1.5kb、1kb、750bp、500bp、250bp;图4B是慢病毒骨架质粒pLenti-3G Basic2的酶切琼脂糖凝胶电泳图,其中,lane 1是pLenti-3G Basic2的Cla I+BamH I酶切电泳结果;lane 2是1kb DNA ladder Marker的电泳结果;
图5是本发明实施例1中重组慢病毒质粒pCAR19-Basic2的酶切预测及酶切琼脂糖凝胶电泳图;图5A是重组慢病毒质粒pCAR19-Basic2的酶切预测图,其中,lane 1是1kb DNAladder Marker,条带从上到下依次为:10kb、8kb、6kb、5kb、4kb、3.5kb、3kb、2.5kb、2kb、1.5kb、1kb、750bp、500bp、250bp;lane 2是pCAR19-Basic2的Nde I+Hpa I酶切预测,条带从上到下依次为:6511bp、2014bp;图5B是重组慢病毒质粒pCAR19-Basic2的酶切琼脂糖凝胶电泳图,其中,lane1是1kb DNA ladder Marker的电泳结果;lane2是pCAR19-Basic2的NdeI+Hpa I酶切电泳结果;
图6是本发明实施例1中重组慢病毒质粒pCAR19-IL6RscFv1、pCAR19-IL6RscFv2和pCAR19-IL6RscFv3的酶切预测及酶切琼脂糖凝胶电泳图;图6A是pCAR19-IL6RscFv1的酶切预测图,其中,lane1是1kb DNA ladder Marker,条带从上到下依次为:10kb、8kb、6kb、5kb、4kb、3.5kb、3kb、2.5kb、2kb、1.5kb、1kb、750bp、500bp、250bp;lane2是pCAR19-IL6RscFv1的ApaL I酶切预测,条带从上到下依次为:4230bp、2137bp、1726bp、1246bp、1054bp、497bp;图6B是pCAR19-IL6RscFv1的酶切琼脂糖凝胶电泳图,其中,lane1是1kb DNA ladder Marker的电泳结果,lane2是pCAR19-IL6RscFv1的ApaL I酶切电泳结果;图6C是pCAR19-IL6RscFv2的酶切预测图,其中,lane1是1kb DNA ladder Marker,条带从上到下依次为:10kb、8kb、6kb、5kb、4kb、3.5kb、3kb、2.5kb、2kb、1.5kb、1kb、750bp、500bp、250bp;lane2是pCAR19-IL6RscFv2的Kpn I酶切预测,条带从上到下依次为:8335bp、2555bp;图6D是pCAR19-IL6RscFv2的酶切琼脂糖凝胶电泳图,其中lane1是1kb DNA ladder Marker的电泳结果;lane2是pCAR19-IL6RscFv2的Kpn I酶切电泳结果;图6E是pCAR19-IL6RscFv3的酶切预测图,其中,lane1是1kb DNA ladder Marker,条带从上到下依次为:10kb、8kb、6kb、5kb、4kb、3.5kb、3kb、2.5kb、2kb、1.5kb、1kb、750bp、500bp、250bp;lane2是pCAR19-IL6RscFv3的PvuII酶切预测:条带从上到下依次为:7703bp、2364bp、823bp;图6F是pCAR19-IL6RscFv3的酶切琼脂糖凝胶电泳图,其中lane1是1kb DNA ladder Marker的电泳结果,lane2是pCAR19-IL6RscFv3的Pvu II酶切电泳结果;图6G是pCAR19-scFv0的酶切预测图,其中,lane1是1kbDNA ladder Marker,条带从上到下依次为:10kb、8kb、6kb、5kb、4kb、3.5kb、3kb、2.5kb、2kb、1.5kb、1kb、750bp、500bp、250bp;lane2是pCAR19-scFv0的Sac II酶切预测,条带从上到下依次为:5577bp、3835bp、895bp、347bp;图6H是pCAR19-scFv0的酶切琼脂糖凝胶电泳图,其中,lane1是1kb DNA ladder Marker的电泳结果,lane2是pCAR19-scFv0的Sac II酶切电泳结果。
图7是本发明实施例2中离子交换色谱法纯化重组慢病毒载体的流程图;
图8是本发明实施例2中重组慢病毒载体的滴度检测结果示意图;
图9是本发明实施例2中重组慢病毒载体的不同纯化方式的支原体检测结果示意图,其中,lane1为DL2000marker,从上到下条带条带从上到下依次为:2kb、1kb、750bp、500bp、250bp、100bp;lane2为阳性对照;lane3为阴性对照;lane4为PBS;lane5为水;lane6为lvCAR19-IL6RscFv1;lane7为lvCAR19-IL6RscFv2;lane8为lvCAR19-IL6RscFv3;lane9为lvCAR19-scFv0;
图10是本发明实施例3中mRNA相对表达量的柱状图;其中,图10A是RT-QPCR结果示意图,表明CAR基因在PBMC细胞内高效转录;图10B是RT-QPCR结果示意图,表明scFv基因在PBMC细胞内高效转录;
图11是本发明实施例3中CAR蛋白表达量的WB检测图,结果表明CAR蛋白在PBMC细胞内高效表达,图11A中,M为蛋白Marker,lane1为PBMC空细胞,lane2为对照病毒MOCK,lane3为lvCAR19-IL6RscFv1,lane4为lvCAR19-IL6RscFv2,lane5为lvCAR19-IL6RscFv3,lane6为lvCAR19-scFv0;图11B是beta-actin内参条带;
图12是本发明实施例3中scFv蛋白表达量的ELISA检测结果图,结果表明scFv蛋白在PBMC细胞中高效表达;
图13是本发明实施例3中重组慢病毒载体转导的PBMC,在不同效靶比条件下共培养,24h后检测对靶细胞的杀伤情况示意图;
图14是本发明实施例3中不同效应细胞分别与靶细胞共培养条件下,12h mRNA转录水平的变化情况示意图;
图15是本发明实施例3中不同组上清培养12h后,PBMC中CRP mRNA转录水平的变化情况示意图。
具体实施方式
下面结合具体实施例进一步阐述此发明。应理解的是,在此描述的特定实施方式通过举例的方式来表示,并不作为对本发明的限制。在不偏离本发明范围的情况下,本发明的主要特征可以用于各种实施方式。实施例1构建重组慢病毒载体
一、材料
1、慢病毒骨架质粒pLenti-3G Basic2,慢病毒包装质粒pPac-GP、pPac-R以及膜蛋白质粒pEnv-G,HEK293T/17细胞、同源重组酶由世翱(上海)生物医药科技有限公司提供;
2、引物:根据引物设计原则设计扩增DNA片段和靶位点所需的引物,该引物由上海生物公司合成,具体为:
EF1α-F:5’-ATTCAAAATTTTATCGATGCTCCGGTGCCCGTCAGT-3’(SEQ ID NO.29)
EF1α-R:5’-TCACGACACCTGAAATGGAAGA-3’(SEQ ID NO.30)
CD8 leader-F:5’-GGTGTCGTGAGGATCCGCCACCATGGCCTTACCAGTGACCGC-3’
(SEQ ID NO.31)
CD8 leader-R:5’-GTGTCATCTGGATGTCCGGCCTGGCGGCGTG-3’(SEQ ID NO.32)
VL-F:5’-CACGCCGCCAGGCCGGACATCCAGATGACACAGACTACATC-3’(SEQ ID NO.33)
VL-R:5’-TGTGATCTCCAGCTTGGTCC-3’(SEQ ID NO.34)
OLC-VH-F:5’-CAAGCTGGAGATCACAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCG
GGTGGCGGCGGATCTGAGGTGAAACTGCAGGAGTCA-3’(SEQ ID NO.35)
VH-R:5’-TGAGGAGACGGTGACTGAGGT-3’(SEQ ID NO.36)
CD8 Hinge-F:5’-AGTCACCGTCTCCTCAACCACGACGCCAGCGCC-3’(SEQ ID NO.37)
CD8 Hinge-R:5’-GTAGATATCACAGGCGAAGTCCA-3’(SEQ ID NO.38)
CD8 Transmembrane-F:5’-CGCCTGTGATATCTACATCTGGGCGCCCTTGGC-3’(SEQ IDNO.39)
CD8 Transmembrane-R:5’-TCTTTCTGCCCCGTTTGCAGTAAAGGGTGATAACCAGTG-3’(SEQID NO.40)
CD137-F:5’-AAACGGGGCAGAAAGAAACTC-3’(SEQ ID NO.41)
CD137-R:5’-TGCTGAACTTCACTCTCAGTTCACATCCTCCTTCTTCTTC-3’(SEQ ID NO.42)
TCR-F:5’-AGAGTGAAGTTCAGCAGGAGCG-3’(SEQ ID NO.43)
TCR-R:5’-GGAGAGGGGCGTCGACTTAGCGAGGGGGCAGGGC-3’(SEQ ID NO.44)
IRES-F:5’-GCCCTGCCCCCTCGCTAAGCCCCTCTCCCTCCCC-3’(SEQ ID NO.45)
IRES-R:5’-CCAGGGAGAAGGCAACTGGACCGAAGGCGCTTGTGGAGAAGGAGTTC
ATGGTGGCATTATCATCGTGTTTTTCAAAGGA-3’(SEQ ID NO.46)
IL6Rs1-F:5’-GTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTGCCTGCTGCCTTCCCTG
CCCCAGACATCCAGATGACCCAGAG-3’(SEQ ID NO.47)
IL6Rs1-R:5’-GCAGCTTTTCGGTTCTGAGGAGACTGTGACGAGGCT-3’(SEQ ID NO.48)
IL6Rs2-F:5’-GTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTGCCTGCTGCCTTCCCTG
CCCCAGAAATTGTGATGACCCAGAG-3’(SEQ ID NO.49)
IL6Rs2-R:5’-GCAGCTTTTCGGTTCGCTGCTCACGGTCACGGTGGT-3’(SEQ ID NO.50)
IL6Rs3-F:5’-GTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTGCCTGCTGCCTTCCCTG
CCCCAGATATTCAGATGACCCAGAG-3’(SEQ ID NO.51)
IL6Rs3-R:5’-GCAGCTTTTCGGTTCGCTGCTCACGGTCACGGTGGT-3’(SEQ ID NO.52)
s0-F:5’-GTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTGCCTGCTGCCTTCCCTG
CCCCATTGTTCTGGATTCCTGCTTCCA-3’(SEQ ID NO.53)
s0-R:5’-GCAGCTTTTCGGTTCTGCAGAGACAGAGACCAGAGT-3’(SEQ ID NO.54)
Fc-F:5’-GAACCGAAAAGCTGCGATAAAAC-3’(SEQ ID NO.55)
Fc-R:5’-CTAGCAATCTAGAGGTTATTTGCCCGGGCTCAGGCTCA-3’(SEQ ID NO.56)
WPRE-QPCR-F:5’-CCTTTCCGGGACTTTCGCTTT-3’(SEQ ID NO.57)
WPRE-QPCR-R:5’-GCAGAATCCAGGTGGCAACA-3’(SEQ ID NO.58)
Actin-QPCR-F:5’-CATGTACGTTGCTATCCAGGC-3’(SEQ ID NO.59)
Actin-QPCR-R:5’-CTCCTTAATGTCACGCACGAT-3’(SEQ ID NO.60)
CAR-QPCR-F:5’-GACTTGTGGGGTCCTTCTCCT-3’(SEQ ID NO.61)
CAR-QPCR-R:5’-GCAGCTACAGCCATCTTCCTC-3’(SEQ ID NO.62)
IL6-QPCR-F:5’-GGATTCAATGAGGAGACTT-3’(SEQ ID NO.63)
IL6-QPCR-R:5’-ATCTGTTCTGGAGGTACT-3’(SEQ ID NO.64)
CRP-QPCR-F:5’-GACATTGGAAATGTGAACATGT-3’(SEQ ID NO.65)
CRP-QPCR-R:5’-CACAGCTGGGGTTTGGTGA-3’(SEQ ID NO.66)
Fc-QPCR-F:5’-GACATTGGAAATGTGAACATGT-3’(SEQ ID NO.67)
Fc-QPCR-R:5’-CACAGCTGGGGTTTGGTGA-3’(SEQ ID NO.68)
3、SEQ ID NO.12~SEQ ID NO.68所示的DNA序列由上海捷瑞生物工程有限公司合成,并以寡核苷酸干粉或者质粒形式保存;
4、工具酶Nde I、Hpa I、Pvu II、Sac II、ApaL I、BamH I、Kpn I、Cla I、T4DNA连接酶均购自NEB公司;
5、高保真酶PrimeSTAR、RN购自Takara公司;
6、0.22μm-0.8μm PES滤器购自millipore公司;
7、质粒抽提试剂盒、琼脂糖凝胶回收试剂盒均购自MN公司;
8、感受态细胞TOP10购自tiangen公司;
9、NaCl、KCl、Na2HPO4.12H2O、KH2PO4、Trypsin、EDTA、CaCl2、NaOH、PEG6000均购自上海生工;
10、Opti-MEM、FBS、DMEM、1640、Pen-Srep、Hepes、购自invitrogen公司;
11、Biotinylated protein L、proteinG-HRP购自GeneScript公司;
12、辣根过氧化物酶标记的二抗、DAB工作液均购自北京中杉金桥;
13、ECL+plusTM Western blotting system购自Amersham公司;
14、DNeasy试剂盒购自上海捷瑞公司;
15、淋巴细胞分离液购自深圳达科为公司;
16、phycoerythrin(PE)-conjugated streptavidin购自BD Bioscience公司;
17、SA-HRP、TMB底物溶液、ELISA反应终止液购自上海翊圣公司;
18、支原体检测试剂盒、内毒素检测试剂盒、CD19+K562细胞购自世翱(上海)公司;
19、LDH检测试剂盒购自promega公司;
二、重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0的构建方法。
参见图3,本发明所述重组慢病毒载体的构建方法如下:
1、将人EF1α启动子、CD8leader嵌合受体信号肽、CD19单链抗体轻链VL、OptimalLinker C、CD19单链抗体重链VH、CD8Hinge嵌合受体铰链、CD8Transmembrane嵌合受体跨膜区、CD137嵌合受体共刺激因子、TCR嵌合受体T细胞激活域片段克隆至慢病毒骨架质粒pLenti-3G Basic2,得到重组慢病毒质粒pCAR19-Basic2,再将scFv片段与Fc片段分别连接到pCAR19-Basic2中,得到IL-6R阻断重组慢病毒质粒pCAR19-IL6RscFv1、pCAR19-IL6RscFv2、pCAR19-IL6RscFv3以及对照pCAR19-scFv0。
(1)将慢病毒骨架质粒pLenti-3G Basic2使用Cla I和BamH I限制性内切酶进行双酶切,产物经过1.5%的琼脂糖凝胶电泳,确认5854bp的片段V1(如图4所示),并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
表1琼脂糖凝胶回收步骤
(2)用引物EF1α-F和EF1α-R以合成的SEQ ID NO.12为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃2min)*35cycle,72℃10min。产物经过1.5%的琼脂糖凝胶电泳,确认1208bp的片段a,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
试剂 | 体积(μl) |
H2O | 32.5 |
5×Buffer(with Mg2+) | 10 |
dNTP(各2.5mM) | 4 |
Primer1(+)(10μM) | 1 |
Primer2(-)(10μM) | 1 |
Template | 1 |
PrimeSTAR | 0.5 |
表2 50μl PCR反应体系
(3)用引物CD8leader-F和CD8leader-R以合成的SEQ ID NO.13为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃30sec)*35cycle,72℃5min。产物经过1.5%的琼脂糖凝胶电泳,确认101bp的片段b,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(4)用引物VL-F和VL-R以合成的SEQ ID NO.14为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃30sec)*35cycle,72℃5min。产物经过1.5%的琼脂糖凝胶电泳,确认336bp的片段c,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(5)用引物OLC-VH-F和VH-R以合成的SEQ ID NO.16为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃30sec)*35cycle,72℃5min。产物经过1.5%的琼脂糖凝胶电泳,确认421bp的片段d,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(6)用引物CD8Hinge-F和CD8Hinge-R以合成的SEQ ID NO.17为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃30sec)*35cycle,72℃5min。产物经过1.5%的琼脂糖凝胶电泳,确认147bp的片段e,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(7)用引物CD8Transmembrane-F和CD8Transmembrane-R以合成的SEQ ID NO.18为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃30sec)*35cycle,72℃5min。产物经过1.5%的琼脂糖凝胶电泳,确认100bp的片段f,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(8)用引物CD137-F和CD137-R以合成的SEQ ID NO.19为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃30sec)*35cycle,72℃5min。产物经过1.5%的琼脂糖凝胶电泳,确认142bp的片段g,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(9)用引物TCR-F和TCR-R以合成的SEQ ID NO.20为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃30sec)*35cycle,72℃5min。产物经过1.5%的琼脂糖凝胶电泳,确认355bp的片段h,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(10)将DNA片段b、c、d各1μl作为模板,使用表3中的体系,除引物外加入Eppendorf管内,PCR循环条件为:98℃3min,(98℃10sec,60℃10sec,72℃30sec)*6cycle,加入引物CD8leader-F/VH-R,(98℃10sec,60℃10sec,72℃40sec)*24cycle,72℃5min。产物经过1.5%的琼脂糖凝胶电泳,确认814bp的片段i,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
试剂 | 体积(μl) |
H2O | 33.5-1*模板数 |
5×Buffer(with Mg2+) | 10 |
dNTP(各2.5mM) | 4 |
Primer1(+)(10μM) | 1 |
Primer2(-)(10μM) | 1 |
Template | 1*模板数 |
PrimeSTAR | 0.5 |
表3 50μl重叠PCR反应体系
(11)将DNA片段e、f、g、h各1μl作为模板,使用表3中的体系,除引物外加入Eppendorf管内,PCR循环条件为:98℃3min,(98℃10sec,60℃10sec,72℃30sec)*6cycle,加入引物CD8Hinge-F/TCR-R,(98℃10sec,60℃10sec,72℃30sec)*24cycle,72℃5min。产物经过1.5%的琼脂糖凝胶电泳,确认704bp的片段j,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(12)将DNA片段V1、a、i、j以5μl总体积且摩尔比1:1:1:1的比例加入Eppendorf管内,加入同源重组酶反应液15μl,混匀后在42℃孵育30分钟,转移至冰上放置2-3分钟,将反应液加入50μl TOP10中,轻轻旋转以混匀内容物,在冰中放置30分钟,将管放到预加温到42℃的恒温水浴锅中热激90秒,快速将管转移到冰浴中,使细胞冷却2-3分钟,每管加900μlLB培养液,然后将管转移到37℃摇床上,温育1小时使细菌复苏,取100μl的转化菌液涂布于Amp LB琼脂平板上,倒置平皿,于恒温培养箱中37℃培养,16小时。
挑取克隆进行菌落PCR鉴定,鉴定正确的克隆即为重组慢病毒质粒pCAR19-Basic2,对正确的克隆进行酶切鉴定(见图5);
(13)将重组慢病毒质粒pCAR19-Basic2使用Sal I和Nhe I限制性内切酶进行双酶切,产物经过1.5%的琼脂糖凝胶电泳,确认8491bp的片段V2,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(14)用引物IRES-F和IRES-R以合成的SEQ ID NO.25为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃2min)*35cycle,72℃10min。产物经过1.5%的琼脂糖凝胶电泳,确认605bp的片段k,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(15)用引物IL6Rs1-F和IL6Rs1-R以合成的SEQ ID NO.21为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃2min)*35cycle,72℃10min。产物经过1.5%的琼脂糖凝胶电泳,确认754bp的片段l,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(16)用引物IL6Rs2-F和IL6Rs2-R以合成的SEQ ID NO.22为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃2min)*35cycle,72℃10min。产物经过1.5%的琼脂糖凝胶电泳,确认777bp的片段m,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(17)用引物IL6Rs3-F和IL6Rs3-R以合成的SEQ ID NO.23为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃2min)*35cycle,72℃10min。产物经过1.5%的琼脂糖凝胶电泳,确认774bp的片段n,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(18)用引物s0-F和s0-R以合成的SEQ ID NO.24为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃2min)*35cycle,72℃10min。产物经过1.5%的琼脂糖凝胶电泳,确认729bp的片段o,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(19)用引物Fc-F和Fc-R以合成的SEQ ID NO.27为模板,使用表2中的体系,PCR循环条件为:98℃3min,(98℃10sec,55℃15sec,72℃2min)*35cycle,72℃10min。产物经过1.5%的琼脂糖凝胶电泳,确认726bp的片段p,并割胶回收置于Eppendorf管内,用MN公司的琼脂糖凝胶回收试剂盒回收相应的片段(见表1),并测定产物的纯度和浓度;
(20)将DNA片段(V2、k、l、p)、(V2、k、m、p)、(V2、k、n、p)、(V2、k、o、p)分别以5μl总体积且摩尔比1:1:1:1的比例加入Eppendorf管内,加入同源重组酶反应液15μl,混匀后在42℃孵育30分钟,转移至冰上放置2-3分钟,将反应液加入50μl TOP10中,轻轻旋转以混匀内容物,在冰中放置30分钟,将管放到预加温到42℃的恒温水浴锅中热激90秒,快速将管转移到冰浴中,使细胞冷却2-3分钟,每管加900μl LB培养液,然后将管转移到37℃摇床上,温育1小时使细菌复苏,取100μl的转化菌液涂布于Amp LB琼脂平板上,倒置平皿,于恒温培养箱中37℃培养,16小时。挑取克隆进行菌落PCR鉴定,鉴定正确的克隆即为重组慢病毒质粒pCAR19-IL6RscFv1、pCAR19-IL6RscFv2、pCAR19-IL6RscFv3以及对照pCAR19-scFv0,对正确的克隆进行酶切鉴定(见图6);
2、重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0的包装。
(1)完全培养基:取出预热好的新鲜培养基,加入10%FBS+5ml Pen-Srep,上下颠倒混匀即可;
(2)1XPBS溶液:称量NaCl 8g,KCl 0.2,Na2HPO4.12H2O 3.58g,KH2PO4 0.24g置于1000ml烧杯中,加入900ml Milli-Q grade超纯水溶解,溶解完成后,使用1000ml量筒定容至1000ml,121℃高温湿热灭菌20min;
(3)0.25%Trypsin溶液:称量Trypsin 2.5g,EDTA 0.19729g置于1000ml烧杯中,加入900ml 1XPBS溶解,溶解完成后,使用1000ml量筒定容至1000ml,0.22μM过滤除菌,长期使用可保存至-20℃冰箱;
(4)0.5M CaCl2溶液:称量36.75g CaCl2用400ml Milli-Q grade超纯水溶解;用Milli-Q grade超纯水将总体积定容至500ml,混匀;0.22μm过滤除菌,分装保存到50ml离心管中,每管45ml左右,4℃保存。
(5)2XHBS溶液:称量4.09g NaCl,0.269g Na2HPO4,5.96g Hepes,用400ml Milli-Q grade超纯水溶解;校准pH仪后,用2M NaOH溶液将HBS溶液的pH调到7.05。调整每瓶HBS的PH消耗2M NaOH为3ml左右;
(6)从液氮罐中取出冻存的HEK293T/17细胞,迅速转移到37℃水浴中,1~2min后转移到超净台中,无菌操作将冻存管中的液体全部转移至10cm2培养皿中,补足含10%FBS的DMEM至8mL/10cm2dish,24h后显微镜观察细胞,细胞汇合的程度大于80%进行传代;
(7)选择细胞状态良好、无污染的HEK293T/17细胞,每2-6个培养皿为一组,将细胞胰酶消化后,用电动移液器吸取4-12ml完全培养基,向每个消化后的培养皿中加2ml,避免培养皿变干;使用1ml移液器将所有细胞吹打成单细胞悬液,转移到培养基瓶中;
(8)将上述2-6个培养皿中的剩余细胞转移到培养基瓶中,并用培养基再冲洗一便培养皿;
(9)盖紧培养基瓶盖,上下颠倒10次左右充分混匀细胞悬液,将细胞传到8-24个10cm2培养皿中,每皿的细胞密度应当约4×106个/10ml完全培养基左右。如果细胞密度和预期的相差较大,则需要对细胞进行计数,然后按照4×106个/皿的量接种;
(10)每6个培养皿整理为一摞,注意保持上下皿之间的配合。将培养皿左右,前后晃动数次,使细胞充分铺开,然后放入5%CO2培养箱。剩余细胞做同样处理;
(11)检查所传代细胞,细胞汇合度应当为70-80%,轮廓饱满,贴壁良好,在细胞培养皿中均匀分布;
(12)为细胞换液,将培养基替换为新鲜完全培养基,每皿9ml,并将培养箱的CO2浓度设定值提高到8%;
(13)按照N+0.5配DNA/CaCl2溶液。每皿HEK293T/17细胞转染质粒量按照下列比例使用:重组慢病毒质粒(20μg),pPac-GP(15μg),pPac-R(10μg),pEnv-G(7.5μg)。取一个新的5ml离心管,加入0.5M CaCl2:0.25ml,重组慢病毒质粒20μg:pPac-GP 15μg:pPac-R 10μg:pEnv-G 7.5μg,补充超纯水至0.5ml盖上盖子,充分混匀;
(14)另取一支5ml离心管,加入0.5ml DNA/CaCl2溶液。打开涡旋振荡器,一只手拿住5ml离心管的上端,使管底接触振荡头,使液体在管壁上散开流动,另一只手拿一把1mL移液枪,吸取0.5mL 2×HBS溶液,缓慢滴加进入离心管,控制流速,以半分钟滴完为宜。2×HBS加入后,继续振荡5秒钟,停止振荡,可直接加入需要转染的细胞中;
(15)取一皿细胞,将离心管中的1mL钙转液滴加进去,尽可能使钙转试剂分布到整个培养皿中;
(16)钙转液加入后,在皿盖上做好标记,将培养皿放还到另一个5%CO2培养箱中。确保培养皿水平放置,每摞培养皿不要超过6个。在5%CO2培养箱中放置(6–8h);
(17)将第一个培养箱的CO2浓度设定值调回到5%;
(18)24小时后,检查细胞状态。细胞汇合度应当为80–85%左右,状态良好。将培养基吸走,更换10ml新鲜的DMEM完全培养基;
(19)48小时后,观察转染效率。绝大多数细胞仍然是贴壁的。可以看到超过95%细胞都会带有绿色荧光。将同一个病毒包装上清液收集到一起,并向培养皿中继续添加10mL新鲜培养基;
(20)72小时后,再次将同一个病毒上清液收集到一起,两次收集的病毒可以放在一起,丢弃培养皿;此时收集的上清里包含了重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0。
实施例2重组慢病毒载体的浓缩及检测
一、离子交换色谱法纯化重组慢病毒载体(如图7所示):
(1)将收集的上清液使用Thermo真空泵,经0.22μm-0.8μm的PES滤器抽滤,除去杂质;
(2)按1:1~1:10的比例往上清中加入1.5M NaCl 250mM Tris-HCl(pH 6-8);
(3)将2个离子交换柱串联放置,用4ml 1M NaOH、4ml 1M NaCl、5ml 0.15M NaCl25mM Tris-HCl(pH 6-8)溶液依次过柱;
(4)将步骤2中获得的溶液通过蠕动泵以1-10ml/min的速度给离子交换柱上样;
(5)全部上清液过柱后,使用10ml 0.15M NaCl 25mM Tris-HCl(pH 6-8)溶液清洗一遍;
(6)根据上样量使用1-5ml 1.5M NaCl 25mM Tris-HCl(pH 6-8)进行洗脱,收集洗脱液;
(7)将洗脱液分成25到50μl一管,冻存到-80℃冰箱,进行长期保存。
二、滴度测定:
(1)取24孔板接种293T细胞。每孔细胞为5×104个,所加培养基体积为500ul,不同种类的细胞生长速度有所差异,进行病毒感染时的细胞融合率为40%-60%;
(2)准备3个无菌EP管,在每个管中加入90ul的新鲜完全培养基(高糖DMEM+10%FBS)接种细胞24小时后,取两个孔的细胞用血球计数板计数,确定感染时细胞的实际数目,记为N;
(3)取待测定的病毒原液10ul加入到第一个管中,轻轻混匀后,取10ul加入到第二个管中,然后依次操作直到最后一管;在每管中加入410ul完全培养基(高糖DMEM+10%FBS),终体积为500ul;
(4)感染开始后20小时,除去培养上清,更换为500μl完全培养基(高糖DMEM+10%FBS),5%CO2继续培养48小时;
(5)72小时后,观察荧光表达情况,正常情况下,荧光细胞数随稀释倍数增加而相应减少,并拍照;
(6)用0.2ml 0.25%胰酶-EDTA溶液消化细胞,在37℃放置1分钟。用培养基吹洗整个细胞面,离心收集细胞。按照DNeasy试剂盒的说明抽提基因组DNA。每个样品管中加入200μl洗脱液洗下DNA并定量;
(7)准备目的DNA检测qPCRmix总管Ⅰ(QPCR引物序列为SEQ ID NO.57---SEQ IDNO.58):
n=number of reactions.例如:总反应数为40,将1ml 2×TaqMan UniversalPCR Master Mix,4μl forward primer,4μl reverse primer,4μl probe和788μl H2O混和。震荡后放在冰上;
(8)准备内参DNA检测qPCRmix管Ⅱ(QPCR引物序列为SEQ ID NO.59---SEQ IDNO.60):
2×TaqMan Master Mix 25μl×n
10×RNaseP primer/probe mix 2.5μl×n
H2O 17.5μl×n
n=number of reactions.例如:总反应数为40,将1ml 2×TaqMan UniversalPCR Master Mix,100μl10×RNaseP primer/probe mix和700μl H2O混和。震荡后放在冰上;
(9)在预冷的96孔PCR板上完成PCR体系建立。从总管Ⅰ中各取45μl加入到A-D各行的孔中,从总管Ⅱ中各取45μl加入到E-G各行的孔中。
(10)分别取5μl质粒标准品和待测样品基因组DNA加入到A-D行中,每个样品重复1次。另留1个孔加入5μl的水做为无模板对照(no-template control)。
(11)分别取5μl基因组标准品和待测样品基因组DNA加入到E-G行中,每个样品重复1次。另留1个孔加入5μl的水做为无模板对照(no-template control)。
(12)所使用定量PCR仪为ABI PRISM 7500定量系统。循环条件设定为:50℃2分钟,95℃10分钟,然后是95℃15秒,60℃1分钟的40个循环。
数据分析:测得的DNA样品中整合的慢病毒载体拷贝数用基因组数加以标定,得到每基因组整合的病毒拷贝数。
滴度(integration units per ml,IU ml-1)的计算公式如下:
IU ml-1=(C×N×D×1000)/V
其中:C=平均每基因组整合的病毒拷贝数
N=感染时细胞的数目(约为1×105)
D=病毒载体的稀释倍数
V=加入的稀释病毒的体积数
(13)重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0的滴度结果(如图8所示)。
三、内毒素测定:
(1)、内毒素工作标准品为15EU/支;
(2)、鲎试剂灵敏度λ=0.25EU/ml,0.5ml/管;
(3)、内毒素标准品稀释:取内毒素标准品一支,分别用BET水按比例稀释成4λ和2λ的溶解,封口膜封口,震荡溶解15min;稀释时每稀释一步均应在漩涡混合器上混匀30s;
(4)、加样:取鲎试剂若干支,每支加入BET水0.5ml溶解,分装至若干支无内毒素试管中,每管0.1ml。其中2支为阴性对照管,加入BET水0.1ml;
2支为阳性对照管,加入2λ浓度的内毒素工作标准品溶液0.1ml;
2支为样品阳性对照管,加入0.1ml含2λ内毒素标准品的样品溶液(稀释20倍的待测样品1ml+4λ的内毒素标准品溶液1ml=2ml含2λ内毒素标准品的稀释40倍样品)。
样品管中加入0.1ml样品,稀释比例见表5,37±1℃水浴(或培养箱)保温60±1min;
表5内毒素稀释比例及对应内毒素含量
(5)、重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0的内毒素检测结果(如表6所示),内毒素含量在0~2.5EU/ml之间,符合要求;
稀释倍数 | 原液 | 5 | 10 | 20 | 40 | 80 | 160 |
对应EU/ml | 0.25 | 1.25 | 2.5 | 5 | 10 | 20 | 40 |
lvCAR19-IL6RscFv1 | (+) | (-) | (-) | (-) | (-) | (-) | (-) |
lvCAR19-IL6RscFv2 | (+) | (+) | (-) | (-) | (-) | (-) | (-) |
lvCAR19-IL6RscFv3 | (+) | (-) | (-) | (-) | (-) | (-) | (-) |
lvCAR19-scFv0 | (+) | (-) | (-) | (-) | (-) | (-) | (-) |
表6重组慢病毒载体的内毒素检测结果
四、支原体测定及比较:
(1)在实验前三日,细胞样品用无抗生素培养基进行培养;
(2)收集1ml细胞悬浮液(细胞数大于1*105),置于1.5ml离心管中;
(3)13000×g离心1min,收集沉淀,弃去培养基;
(4)加入500ul PBS用枪头吹吸或涡旋振荡,重悬沉淀。13000×g离心5min;
(5)步骤4重复一次;
(6)加入50μl Cell Lysis Buffer,用枪头吹吸,充分混匀后,在55℃水浴中孵育20min;
(7)将样品置于95℃中加热5min;
(8)13000×g离心5min后,取5μl上清作为模板,25μlPCR反应体系为:ddH20 6.5μl、Myco Mix 1μl、2x Taq Plus Mix Master(Dye Plus)12.5μl、模板5μl;PCR循环条件为:95℃30sec,(95℃30sec,56℃30sec,72℃30sec)*30cycle,72℃5min。
(9)支原体检测结果显示(如图9所示),重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、
lvCAR19-IL6RscFv3、lvCAR19-scFv0均不含支原体。
实施例3重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0的功能检测。
一、CAR基因的细胞水平表达检测:
(1)重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0和对照病毒Mock感染PBMC细胞后,收集细胞采用RT-PCR进行CAR基因和scFv基因mRNA转录水平的检测,验证CAR基因和scFv基因的表达,如果CAR基因和scFv基因mRNA转录水平增高,则说明CAR基因和scFv基因的转录水平表达成功;
(2)重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0和对照病毒Mock感染PBMC细胞后,收集细胞采用western blot进行CAR蛋白表达水平的检测,验证CAR基因的表达,如果CAR蛋白表达水平增高,则说明CAR基因的翻译水平表达成功;
(3)重组慢病毒载体lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0和对照病毒Mock感染PBMC细胞后,收集细胞培养上清采用ELISA进行scFv蛋白表达水平的检测,验证scFv基因的表达,如果scFv蛋白表达水平增高,则说明scFv基因的翻译水平表达成功;
(4)分别将MOI=15的lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0和对照病毒Mock感染细胞,48h后提取6孔板中细胞的总RNA和总蛋白分别进行荧光定量PCR实验和免疫印迹实验。具体步骤:包被6孔板的四个孔,每个孔加入相应的PBS和RN,4℃过夜。12小时后按MOI=15包被病毒,37℃培养箱放置5h;取出的6孔板,弃掉病毒上清,用PBS洗两遍,按1*106/孔,包被PBMC(用淋巴细胞分离液从人血中分离),加入500ul培养基(含10%血清、20U/ml IL-2、Polybrene 8ug/ml)。静置20min,1000g20℃离心30min,37℃培养48h。
(5)Trizol法提取6孔板中PBMC细胞的总RNA,逆转录扩增cDNA,用CAR基因QPCR引物(序列为SEQ IDNO.61---SEQ ID NO.62)和scFv基因QPCR引物(序列为SEQ ID NO.67---SEQ ID NO.68)进行荧光定量PCR实验,反应体系见表7,以内参Actin为对照组,验证其mRNA的转录情况。
试剂 | 体积(μl) |
SYBR premix ex taq: | 10μl |
ROX Reverse Dye(50x) | 0.4μl |
上游引物(2.5μM): | 0.5μl |
下游引物(2.5μM): | 0.5μl |
cDNA | 1.0μl |
ddH2O | 7.6μl |
表7 20μl qPCR反应体系
(6)蛋白免疫印迹(Western Blot)通过聚丙烯酰胺凝胶电泳将从PBMC中提取的总蛋白质按相对分子质量分离。采用湿转(4℃,400mA,120min),将蛋白转移到PVDF膜上。用封闭液(含5%脱脂牛奶的TBST溶液)室温封闭PVDF膜1h,封闭液1:1000稀释Biotinylatedprotein L,然后与封闭好的PVDF膜室温孵育4℃过夜。TBST洗膜3次,每次10min。封闭液1:500稀释相应的SA-HRP,室温下孵育PVDF膜2h,TBST洗膜3次,每次10min。采用Amersham公司ECL+plusTM Western blotting system试剂盒进行显色。X光显影获得显示条带的胶片。
(7)酶联免疫吸附测定(Enzyme Linked ImmunoSorbent Assay,ELISA)通过将1:2、1:5、1:10稀释的细胞培养上清包被至96孔板中,同时设置阴性对照、阳性对照和空白孔,4℃过夜。次日洗涤3次,于反应孔中,加入新鲜1:10000稀释的proteinG-HRP 0.1ml,37℃孵育30-60分钟,洗涤,最后一遍用纯水洗涤。于各反应孔中加入的TMB底物溶液0.1ml,37℃孵育10~30分钟。于各反应孔中加入ELISA反应终止液0.05ml。在酶标仪上,于405nm处,测各孔OD值。
(8)RT-QPCR检测显示,重组慢病毒载体感染PBMC后的CAR基因和scFv基因的转录水平比空细胞有明显升高(如图10所示),说明CAR基因和scFv基因的转录水平表达成功。
(9)蛋白免疫印迹(Western Blot)的结果表明,重组慢病毒载体感染PBMC后CAR蛋白的表达水平比对照病毒MOCK和空细胞有明显升高(如图11所示),说明CAR基因的翻译水平表达成功。
(10)酶联免疫吸附测定(ELISA)的结果表明,重组慢病毒载体感染PBMC后scFv蛋白的表达水平比对照病毒MOCK和空细胞有明显升高(如图12所示),说明scFv基因的翻译水平表达成功。
二、细胞杀伤实验效果评估。
(1)分别培养CD19+K562细胞和PBMC细胞;
(2)实验开始前4天,分别用MOI=15的lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0的病毒感染PBMC细胞,培养72-96h后可安排开始实验;
(3)收集靶细胞(CD19+K562)4x105cells和效应细胞(lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0分别转导的PBMC细胞)2.8x106cells,800g,6min离心,弃上清;
(4)用1ml 1xPBS溶液分别重悬靶细胞和效应细胞,800g,6min离心,弃上清;
(5)重复步骤3一次;
(6)用700ul培养基(1640培养基+10%FBS)重悬效应细胞,用2ml培养基(1640培养基+10%FBS)重悬靶细胞;
(7)设置效靶比为1:1、5:1、10:1的实验孔,并设置对照组,每组3个复孔;
(8)250xg,5min平板离心;
(9)37℃5%CO2培养箱中培养24小时;
(10)250xg,5min平板离心;
(11)取每个孔的50ul上清到新96孔板中,并且每孔加入50ul底物溶液(避光操作);
(12)避光孵育25分钟;
(13)每孔加入50ul终止液;
(14)酶标仪检测490nm吸光度;
(15)将3个复孔取平均值;将所有实验孔、靶细胞孔和效应细胞孔的吸光值减去培养基背景吸光值的均值;将靶细胞最大值的吸光值减去体积校正对照吸光值的均值。
(16)将步骤15中获得的经过校正的值带入下面公式,计算每个效靶比所产生的细胞毒性百分比。结果如图13所示,lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0重组慢病毒载体转导的PBMC细胞在几个效靶比条件下杀伤效率明显高于PBMC空细胞和对照病毒,说明scFv基因的表达对CAR基因的功能影响较小。
杀伤效率=(实验孔-效应细胞孔-靶细胞孔)/(靶细胞最大孔-靶细胞孔)X100%。
三、IL-6R阻断效果评估(IL-6和CRP mRNA转录水平)。
(1)分别培养CD19+K562细胞和PBMC细胞;
(2)实验开始前4天,分别用MOI=15的lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0的病毒感染PBMC细胞,培养72-96h后可安排开始实验;
(3)收集靶细胞(CD19+K562)4x105cells和效应细胞(lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0分别转导的PBMC细胞)2.8x106cells,800g,6min离心,弃上清;(4)用1ml 1xPBS溶液分别重悬靶细胞和效应细胞,800g,6min离心,弃上清;
(5)重复步骤4一次;
(6)用700ul培养基(1640培养基+10%FBS)重悬效应细胞,用2ml培养基(1640培养基+10%FBS)重悬靶细胞;
(7)设置效靶比为10:1的实验孔,并设置对照组;
(8)250xg,5min平板离心;
(9)37℃5%CO2培养箱中共培养12小时,1000xg,2min平板离心,收集细胞抽总mRNA,反转cDNA,检测IL-6mRNA转录水平;
(10)上清中加入空白PBMC细胞,继续37℃5%CO2培养箱中共培养至24小时,1000xg,2min平板离心,收集细胞抽总mRNA,反转cDNA,检测CRP mRNA转录水平;
(11)用IL-6基因QPCR引物(序列为SEQ ID NO.63---SEQ ID NO.64)和CRP基因QPCR引物(序列为SEQ ID NO.65---SEQ ID NO.66)进行荧光定量PCR实验,反应体系见表6,以内参Actin为对照组,验证其mRNA的转录情况。
(12)RT-QPCR检测结果显示,lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0转导的PBMC并与靶细胞孵育后,IL-6基因的mRNA水平与Mock组和空细胞组相比明显升高,lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0四组之间的IL-6基因的mRNA水平则没有太大差别(如图14所示),而其后通过检测不同组上清培养的PBMC细胞中CRP基因的mRNA水平发现,lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3、lvCAR19-scFv0三组与对照病毒lvCAR19-scFv0组相比CRP mRNA转录水平明显降低,其中lvCAR19-IL6RscFv1组的CRP基因的转录mRNA水平降低最为明显(如图15所示),说明lvCAR19-IL6RscFv1、lvCAR19-IL6RscFv2、lvCAR19-IL6RscFv3组均能有效阻断IL-6信号通路(其中lvCAR19-IL6RscFv1阻断IL-6信号通路效果最明显),进而在临床上能有效缓解CRS。
序列表
<110>上海优卡迪生物医药科技有限公司
<120>一种封闭IL6R的用于缓解CRS的CAR-T转基因载体及其构建方法和应用
<130> HJ16-12295
<160> 68
<170> PatentIn version 3.5
<210> 1
<211> 861
<212> DNA
<213>人工序列
<400> 1
atgagtattc aacatttccg tgtcgccctt attccctttt ttgcggcatt ttgccttcct 60
gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca 120
cgagtgggtt acatcgaact ggatctcaac agcggtaaga tccttgagag ttttcgcccc 180
gaagaacgtt ttccaatgat gagcactttt aaagttctgc tatgtggcgc ggtattatcc 240
cgtattgacg ccgggcaaga gcaactcggt cgccgcatac actattctca gaatgacttg 300
gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt aagagaatta 360
tgcagtgctg ccataaccat gagtgataac actgcggcca acttacttct gacaacgatc 420
ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt aactcgcctt 480
gatcgttggg aaccggagct gaatgaagcc ataccaaacg acgagcgtga caccacgatg 540
cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact tactctagct 600
tcccggcaac aattaataga ctggatggag gcggataaag ttgcaggacc acttctgcgc 660
tcggcccttc cggctggctg gtttattgct gataaatctg gagccggtga gcgtgggtct 720
cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt agttatctac 780
acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgctga gataggtgcc 840
tcactgatta agcattggta a 861
<210> 2
<211> 674
<212> DNA
<213>人工序列
<400> 2
cccgtagaaa agatcaaagg atcttcttga gatccttttt ttctgcgcgt aatctgctgc 60
ttgcaaacaa aaaaaccacc gctaccagcg gtggtttgtt tgccggatca agagctacca 120
actctttttc cgaaggtaac tggcttcagc agagcgcaga taccaaatac tgtccttcta 180
gtgtagccgt agttaggcca ccacttcaag aactctgtag caccgcctac atacctcgct 240
ctgctaatcc tgttaccagt ggctgctgcc agtggcgata agtcgtgtct taccgggttg 300
gactcaagac gatagttacc ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc 360
acacagccca gcttggagcg aacgacctac accgaactga gatacctaca gcgtgagcta 420
tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca ggtatccggt aagcggcagg 480
gtcggaacag gagagcgcac gagggagctt ccagggggaa acgcctggta tctttatagt 540
cctgtcgggt ttcgccacct ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg 600
cggagcctat ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg 660
ccttttgctc acat 674
<210> 3
<211> 147
<212> DNA
<213>人工序列
<400> 3
atcccgcccc taactccgcc cagttccgcc cattctccgc cccatggctg actaattttt 60
tttatttatg cagaggccga ggccgcctcg gcctctgagc tattccagaa gtagtgagga 120
ggcttttttg gaggcctaga cttttgc 147
<210> 4
<211> 228
<212> DNA
<213>人工序列
<400> 4
gtagtcttat gcaatactct tgtagtcttg caacatggta acgatgagtt agcaacatgc 60
cttacaagga gagaaaaagc accgtgcatg ccgattggtg gaagtaaggt ggtacgatcg 120
tgccttatta ggaaggcaac agacgggtct gacatggatt ggacgaacca ctgaattgcc 180
gcattgcaga gatattgtat ttaagtgcct agctcgatac aataaacg 228
<210> 5
<211> 180
<212> DNA
<213>人工序列
<400> 5
ggtctctctg gttagaccag atctgagcct gggagctctc tggctaacta gggaacccac 60
tgcttaagcc tcaataaagc ttgccttgag tgcttcaagt agtgtgtgcc cgtctgttgt 120
gtgactctgg taactagaga tccctcagac ccttttagtc agtgtggaaa atctctagca 180
<210> 6
<211> 234
<212> DNA
<213>人工序列
<400> 6
tgctagagat tttccacact gactaaaagg gtctgaggga tctctagtta ccagagtcac 60
acaacagacg ggcacacact acttgaagca ctcaaggcaa gctttattga ggcttaagca 120
gtgggttccc tagttagcca gagagctccc aggctcagat ctggtctaac cagagagacc 180
cagtacaagc aaaaagcaga tcttattttc gttgggagtg aattagccct tcca 234
<210> 7
<211> 353
<212> DNA
<213>人工序列
<400> 7
atgggtgcga gagcgtcagt attaagcggg ggagaattag atcgcgatgg gaaaaaattc 60
ggttaaggcc agggggaaag aaaaaatata aattaaaaca tatagtatgg gcaagcaggg 120
agctagaacg attcgcagtt aatcctggcc tgttagaaac atcagaaggc tgtagacaaa 180
tactgggaca gctacaacca tcccttcaga caggatcaga agaacttaga tcattatata 240
atacagtagc aaccctctat tgtgtgcatc aaaggataga gataaaagac accaaggaag 300
ctttagacaa gatagaggaa gagcaaaaca aaagtaagac caccgcacag caa 353
<210> 8
<211> 233
<212> DNA
<213>人工序列
<400> 8
aggagctttg ttccttgggt tcttgggagc agcaggaagc actatgggcg cagcctcaat 60
gacgctgacg gtacaggcca gacaattatt gtctggtata gtgcagcagc agaacaattt 120
gctgagggct attgaggcgc aacagcatct gttgcaactc acagtctggg gcatcaagca 180
gctccaggca agaatcctgg ctgtggaaag atacctaaag gatcaacagc tcc 233
<210> 9
<211> 489
<212> DNA
<213>人工序列
<400> 9
tggggatttg gggttgctct ggaaaactca tttgcaccac tgctgtgcct tggaatgcta 60
gttggagtaa taaatctctg gaacagattg gaatcacacg acctggatgg agtgggacag 120
agaaattaac aattacacaa gcttaataca ctccttaatt gaagaatcgc aaaaccagca 180
agaaaagaat gaacaagaat tattggaatt agataaatgg gcaagtttgt ggaattggtt 240
taacataaca aattggctgt ggtatataaa attattcata atgatagtag gaggcttggt 300
aggtttaaga atagtttttg ctgtactttc tatagtgaat agagttaggc agggatattc 360
accattatcg tttcagaccc acctcccaac cccgagggga cccgacaggc ccgaaggaat 420
agaagaagaa ggtggagaga gagacagaga cagatccatt cgattagtga acggatctcg 480
acggttaac 489
<210> 10
<211> 119
<212> DNA
<213>人工序列
<400> 10
ttttaaaaga aaagggggga ttggggggta cagtgcaggg gaaagaatag tagacataat 60
agcaacagac atacaaacta aagaattaca aaaacaaatt acaaaaattc aaaatttta 119
<210> 11
<211> 592
<212> DNA
<213>人工序列
<400> 11
aatcaacctc tggattacaa aatttgtgaa agattgactg gtattcttaa ctatgttgct 60
ccttttacgc tatgtggata cgctgcttta atgcctttgt atcatgctat tgcttcccgt 120
atggctttca ttttctcctc cttgtataaa tcctggttgc tgtctcttta tgaggagttg 180
tggcccgttg tcaggcaacg tggcgtggtg tgcactgtgt ttgctgacgc aacccccact 240
ggttggggca ttgccaccac ctgtcagctc ctttccggga ctttcgcttt ccccctccct 300
attgccacgg cggaactcat cgccgcctgc cttgcccgct gctggacagg ggctcggctg 360
ttgggcactg acaattccgt ggtgttgtcg gggaaatcat cgtcctttcc ttggctgctc 420
gcctgtgttg ccacctggat tctgcgcggg acgtccttct gctacgtccc ttcggccctc 480
aatccagcgg accttccttc ccgcggcctg ctgccggctc tgcggcctct tccgcgtctt 540
cgccttcgcc ctcagacgag tcggatctcc ctttgggccg cctccccgcc tg 592
<210> 12
<211> 1178
<212> DNA
<213>人工序列
<400> 12
gctccggtgc ccgtcagtgg gcagagcgca catcgcccac agtccccgag aagttggggg 60
gaggggtcgg caattgaacc ggtgcctaga gaaggtggcg cggggtaaac tgggaaagtg 120
atgtcgtgta ctggctccgc ctttttcccg agggtggggg agaaccgtat ataagtgcag 180
tagtcgccgt gaacgttctt tttcgcaacg ggtttgccgc cagaacacag gtaagtgccg 240
tgtgtggttc ccgcgggcct ggcctcttta cgggttatgg cccttgcgtg ccttgaatta 300
cttccacctg gctgcagtac gtgattcttg atcccgagct tcgggttgga agtgggtggg 360
agagttcgag gccttgcgct taaggagccc cttcgcctcg tgcttgagtt gaggcctggc 420
ctgggcgctg gggccgccgc gtgcgaatct ggtggcacct tcgcgcctgt ctcgctgctt 480
tcgataagtc tctagccatt taaaattttt gatgacctgc tgcgacgctt tttttctggc 540
aagatagtct tgtaaatgcg ggccaagatc tgcacactgg tatttcggtt tttggggccg 600
cgggcggcga cggggcccgt gcgtcccagc gcacatgttc ggcgaggcgg ggcctgcgag 660
cgcggccacc gagaatcgga cgggggtagt ctcaagctgg ccggcctgct ctggtgcctg 720
gcctcgcgcc gccgtgtatc gccccgccct gggcggcaag gctggcccgg tcggcaccag 780
ttgcgtgagc ggaaagatgg ccgcttcccg gccctgctgc agggagctca aaatggagga 840
cgcggcgctc gggagagcgg gcgggtgagt cacccacaca aaggaaaagg gcctttccgt 900
cctcagccgt cgcttcatgt gactccactg agtaccgggc gccgtccagg cacctcgatt 960
agttctcgag cttttggagt acgtcgtctt taggttgggg ggaggggttt tatgcgatgg 1020
agtttcccca cactgagtgg gtggagactg aagttaggcc agcttggcac ttgatgtaat 1080
tctccttgga atttgccctt tttgagtttg gatcttggtt cattctcaag cctcagacag 1140
tggttcaaag tttttttctt ccatttcagg tgtcgtga 1178
<210> 13
<211> 63
<212> DNA
<213>人工序列
<400> 13
atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
ccg 63
<210> 14
<211> 321
<212> DNA
<213>人工序列
<400> 14
gacatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60
atcagttgca gggcaagtca ggacattagt aaatatttaa attggtatca gcagaaacca 120
gatggaactg ttaaactcct gatctaccat acatcaagat tacactcagg agtcccatca 180
aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa 240
gaagatattg ccacttactt ttgccaacag ggtaatacgc ttccgtacac gttcggaggg 300
gggaccaagc tggagatcac a 321
<210> 15
<211> 45
<212> DNA
<213>人工序列
<400> 15
ggtggcggtg gctcgggcgg tggtgggtcg ggtggcggcg gatct 45
<210> 16
<211> 360
<212> DNA
<213>人工序列
<400> 16
gaggtgaaac tgcaggagtc aggacctggc ctggtggcgc cctcacagag cctgtccgtc 60
acatgcactg tctcaggggt ctcattaccc gactatggtg taagctggat tcgccagcct 120
ccacgaaagg gtctggagtg gctgggagta atatggggta gtgaaaccac atactataat 180
tcagctctca aatccagact gaccatcatc aaggacaact ccaagagcca agttttctta 240
aaaatgaaca gtctgcaaac tgatgacaca gccatttact actgtgccaa acattattac 300
tacggtggta gctatgctat ggactactgg ggccaaggaa cctcagtcac cgtctcctca 360
<210> 17
<211> 141
<212> DNA
<213>人工序列
<400> 17
accacgacgc cagcgccgcg accaccaaca ccggcgccca ccatcgcgtc gcagcccctg 60
tccctgcgcc cagaggcgtg ccggccagcg gcggggggcg cagtgcacac gagggggctg 120
gacttcgcct gtgatatcta c 141
<210> 18
<211> 66
<212> DNA
<213>人工序列
<400> 18
atctgggcgc ccttggccgg gacttgtggg gtccttctcc tgtcactggt tatcaccctt 60
tactgc 66
<210> 19
<211> 126
<212> DNA
<213>人工序列
<400> 19
aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa 60
actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt 120
gaactg 126
<210> 20
<211> 336
<212> DNA
<213>人工序列
<400> 20
agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60
tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120
cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180
gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240
cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300
tacgacgccc ttcacatgca ggccctgccc cctcgc 336
<210> 21
<211> 723
<212> DNA
<213>人工序列
<400> 21
gacatccaga tgacccagag cccaagcagc ctgagcgcca gcgtgggtga cagagtgacc 60
atcacctgta gagccagcca ggacatcagc agttacctga attggtacca gcagaagcca 120
ggaaaggctc caaagctgct gatctactac acctccagac tgcactctgg tgtgccaagc 180
agattcagcg gtagcggtag cggtaccgac ttcaccttca ccatcagcag cctccagcca 240
gaggacatcg ctacctacta ctgccaacag ggtaacacgc ttccatacac gttcggccaa 300
gggaccaagg tggaaatcaa aggtggcggt ggctcgggcg gtggtgggtc gggtggcggc 360
ggatctcagg tccaactgca ggagagcggt ccaggtcttg tgagacctag ccagaccctg 420
agcctgacct gcaccgtgtc tggctactca attaccagcg atcatgcctg gagctgggtt 480
cgccagccac ctggacgagg tcttgagtgg attggataca ttagttatag tggaatcaca 540
acctataatc catctctcaa atccagagtg acaatgctga gagacaccag caagaaccag 600
ttcagcctga gactcagcag cgtgacagcc gccgacaccg cggtttatta ttgtgcaaga 660
tccctagctc ggactacggc tatggactac tggggtcaag gcagcctcgt cacagtctcc 720
tca 723
<210> 22
<211> 747
<212> DNA
<213>人工序列
<400> 22
gaaattgtga tgacccagag cccggcgacc ctgagcgtga gcccgggcga acgcgcgacc 60
attacctgcc gcgcgagcca gggcattagc agctggctgg cgtggtatca gcagaaaccg 120
ggccaggcgc cgcgcctgct gatttatggc gcgagcaccc gcgcgaccgg cattccggcg 180
cgctttagcg gcagcggcag cggcaccgat tttaccctga ccattagcag cctgcagccg 240
gaagattttg cggtgtatta ttgccagcag tatagcagct ggccgccgta tacctttggc 300
cagggcacca aactggaaat taaaggtggc ggtggctcgg gcggtggtgg gtcgggtggc 360
ggcggatctg aagtgcagct ggtggaaagc ggcggcaacc tggtgcagcc gggccgcagc 420
ctgcgcctga gctgcgcggc gagcggcttt atttttgatg attatgcgat gcattgggtg 480
cgccaggcgc cgggcaaagg cctggaatgg gtgagcggca ttagctggaa cagcggcagc 540
attggctatg cggatagcgt gaaaggccgc tttaccatta gccgcgataa cgcgaaaaac 600
agcctgtatc tgcagatgaa cagcctgcgc gcggaagata ccgcgctgta ttattgcgcg 660
aaagatggcg gcagcagctg gctgccgttt gtgtattatt atggcatgga tgtgtggggc 720
cagggcacca ccgtgaccgt gagcagc 747
<210> 23
<211> 744
<212> DNA
<213>人工序列
<400> 23
gatattcaga tgacccagag cccgagcagc gtgagcgcga gcgtgggcga tcgcgtgacc 60
ctgagctgcc gcgcgagcca gagcattagc agcaactttg cgtggtatca gcagaaaccg 120
ggcaaagcgc cgaaactgct gatttatggc gcgagcagcc tggaaagcgg cgtgccgagc 180
cgctttagcg gcagcggcag cggcaccgat tttaccctga ccattagcag cctgcagagc 240
gaagattttg cgagctatta ttgccagcag gcgaacagct ttccgtatac ctttggccag 300
ggcaccaaac tggaaattaa aggtggcggt ggctcgggcg gtggtgggtc gggtggcggc 360
ggatctgaag tgcagctggt ggaaagcggc ggcggcctgg tgcagccggg ccgcagcctg 420
cgcctgagct gcgcggcgag cggctttatt tttgatgatt atgcgatgca ttgggtgcgc 480
caggcgccgg gcaaaggcct ggaatgggtg agcggcatta gctggaacag cggcagcatt 540
ggctatgcgg atagcgtgaa aggccgcttt accattagcc gcgataacgc gaaaaacagc 600
ctgtatctgc agatgaacag cctgcgcgcg gaagataccg cgctgtatta ttgcgcgaaa 660
gatggcggca gcagctggct gccgtttgtg tattattatg gcatggatgt gtggggccag 720
ggcaccaccg tgaccgtgag cagc 744
<210> 24
<211> 699
<212> DNA
<213>人工序列
<400> 24
ttgttctgga ttcctgcttc catcagtgat gttgtgatga cccaaactgt cagtcttgga 60
gatcaagctt ccatctcttg cagatctagt cagaaccttg tacacaacaa tggaaacacc 120
tatttatatt ggttcctgca gaagtcaggc cagtctccaa agctcctgat ttatagggct 180
tccatccgat tttctggggt cccagacagg ttcagtggca gtggatcaga gacagatttc 240
acactcaaga tcagcagagt ggaggcttat ttctgctttc aaggtacaca tgttccgtgg 300
acgttcggtg gaggcaccaa gctggaaatc aaaggtggcg gtggctcggg cggtggtggg 360
tcgggtggcg gcggatctga ggtgctgctg caacagtctg gacctgagct ggtgaagata 420
ccctgcaagg cttctggata cacattcact gactacaaca tggactggat gaagcagagc 480
catggaaaga gccttgagtg gattggagat attaatccta agagtggtaa ttccatctac 540
aaccagaagt tcaagggcaa ggccacactg actgtagaca agtcctccag cacagcctac 600
atggagctcc gcagcctgac atctgaggac actgcagtct atgactggtc tgcctggttt 660
gctttctggg gccaagggac tctggtctct gtctctgca 699
<210> 25
<211> 575
<212> DNA
<213>人工序列
<400> 25
gcccctctcc ctcccccccc cctaacgtta ctggccgaag ccgcttggaa taaggccggt 60
gtgcgtttgt ctatatgtta ttttccacca tattgccgtc ttttggcaat gtgagggccc 120
ggaaacctgg ccctgtcttc ttgacgagca ttcctagggg tctttcccct ctcgccaaag 180
gaatgcaagg tctgttgaat gtcgtgaagg aagcagttcc tctggaagct tcttgaagac 240
aaacaacgtc tgtagcgacc ctttgcaggc agcggaaccc cccacctggc gacaggtgcc 300
tctgcggcca aaagccacgt gtataagata cacctgcaaa ggcggcacaa ccccagtgcc 360
acgttgtgag ttggatagtt gtggaaagag tcaaatggct cacctcaagc gtattcaaca 420
aggggctgaa ggatgcccag aaggtacccc attgtatggg atctgatctg gggcctcggt 480
gcacatgctt tacatgtgtt tagtcgaggt taaaaaacgt ctaggccccc cgaaccacgg 540
ggacgtggtt ttcctttgaa aaacacgatg ataat 575
<210> 26
<211> 87
<212> DNA
<213>人工序列
<400> 26
atgaactcct tctccacaag cgccttcggt ccagttgcct tctccctggg gctgctcctg 60
gtgttgcctg ctgccttccc tgcccca 87
<210> 27
<211> 696
<212> DNA
<213>人工序列
<400> 27
gaaccgaaaa gctgcgataa aacccatacc tgcccgccgt gcccggcgcc ggaactgctg 60
ggcggcccga gcgtgtttct gtttccgccg aaaccgaaag ataccctgat gattagccgc 120
accccggaag tgacctgcgt ggtggtggat gtgagccatg aagatccgga agtgaaattt 180
aactggtatg tggatggcgt ggaagtgcat aacgcgaaaa ccaaaccgcg cgaagaacag 240
tataacagca cctatcgcgt ggtgagcgtg ctgaccgtgc tgcatcagga ttggctgaac 300
ggcaaagaat ataaatgcaa agtgagcaac aaagcgctgc cggcgccgat tgaaaaaacc 360
attagcaaag cgaaaggcca gccgcgcgaa ccgcaggtgt ataccctgcc gccgagccgc 420
gaagaaatga ccaaaaacca ggtgagcctg acctgcctgg tgaaaggctt ttatccgagc 480
gatattgcgg tggaatggga aagcaacggc cagccggaaa acaactataa aaccaccccg 540
ccggtgctgg atagcgatgg cagctttttt ctgtatagca aactgaccgt ggataaaagc 600
cgctggcagc agggcaacgt gtttagctgc agcgtgatgc atgaagcgct gcataaccat 660
tatacccaga aaagcctgag cctgagcccg ggcaaa 696
<210> 28
<211> 123
<212> DNA
<213>人工序列
<400> 28
aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60
gggcccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120
tcc 123
<210> 29
<211> 36
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 29
attcaaaatt ttatcgatgc tccggtgccc gtcagt 36
<210> 30
<211> 22
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 30
tcacgacacc tgaaatggaa ga 22
<210> 31
<211> 42
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 31
ggtgtcgtga ggatccgcca ccatggcctt accagtgacc gc 42
<210> 32
<211> 31
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 32
gtgtcatctg gatgtccggc ctggcggcgt g 31
<210> 33
<211> 41
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 33
cacgccgcca ggccggacat ccagatgaca cagactacat c 41
<210> 34
<211> 20
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 34
tgtgatctcc agcttggtcc 20
<210> 35
<211> 82
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 35
caagctggag atcacaggtg gcggtggctc gggcggtggt gggtcgggtg gcggcggatc 60
tgaggtgaaa ctgcaggagt ca 82
<210> 36
<211> 21
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 36
tgaggagacg gtgactgagg t 21
<210> 37
<211> 33
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 37
agtcaccgtc tcctcaacca cgacgccagc gcc 33
<210> 38
<211> 23
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 38
gtagatatca caggcgaagt cca 23
<210> 39
<211> 33
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 39
cgcctgtgat atctacatct gggcgccctt ggc 33
<210> 40
<211> 39
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 40
tctttctgcc ccgtttgcag taaagggtga taaccagtg 39
<210> 41
<211> 21
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 41
aaacggggca gaaagaaact c 21
<210> 42
<211> 40
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 42
tgctgaactt cactctcagt tcacatcctc cttcttcttc 40
<210> 43
<211> 22
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 43
agagtgaagt tcagcaggag cg 22
<210> 44
<211> 34
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 44
ggagaggggc gtcgacttag cgagggggca gggc 34
<210> 45
<211> 34
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 45
gccctgcccc ctcgctaagc ccctctccct cccc 34
<210> 46
<211> 79
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 46
ccagggagaa ggcaactgga ccgaaggcgc ttgtggagaa ggagttcatg gtggcattat 60
catcgtgttt ttcaaagga 79
<210> 47
<211> 74
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 47
gttgccttct ccctggggct gctcctggtg ttgcctgctg ccttccctgc cccagacatc 60
cagatgaccc agag 74
<210> 48
<211> 36
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 48
gcagcttttc ggttctgagg agactgtgac gaggct 36
<210> 49
<211> 74
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 49
gttgccttct ccctggggct gctcctggtg ttgcctgctg ccttccctgc cccagaaatt 60
gtgatgaccc agag 74
<210> 50
<211> 36
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 50
gcagcttttc ggttcgctgc tcacggtcac ggtggt 36
<210> 51
<211> 74
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 51
gttgccttct ccctggggct gctcctggtg ttgcctgctg ccttccctgc cccagatatt 60
cagatgaccc agag 74
<210> 52
<211> 36
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 52
gcagcttttc ggttcgctgc tcacggtcac ggtggt 36
<210> 53
<211> 76
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 53
gttgccttct ccctggggct gctcctggtg ttgcctgctg ccttccctgc cccattgttc 60
tggattcctg cttcca 76
<210> 54
<211> 36
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 54
gcagcttttc ggttctgcag agacagagac cagagt 36
<210> 55
<211> 23
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 55
gaaccgaaaa gctgcgataa aac 23
<210> 56
<211> 38
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 56
ctagcaatct agaggttatt tgcccgggct caggctca 38
<210> 57
<211> 21
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 57
cctttccggg actttcgctt t 21
<210> 58
<211> 20
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 58
gcagaatcca ggtggcaaca 20
<210> 59
<211> 21
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 59
catgtacgtt gctatccagg c 21
<210> 60
<211> 21
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 60
ctccttaatg tcacgcacga t 21
<210> 61
<211> 21
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 61
gacttgtggg gtccttctcc t 21
<210> 62
<211> 21
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 62
gcagctacag ccatcttcct c 21
<210> 63
<211> 19
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 63
ggattcaatg aggagactt 19
<210> 64
<211> 18
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 64
atctgttctg gaggtact 18
<210> 65
<211> 22
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 65
gacattggaa atgtgaacat gt 22
<210> 66
<211> 19
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 66
cacagctggg gtttggtga 19
<210> 67
<211> 22
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 67
gacattggaa atgtgaacat gt 22
<210> 68
<211> 19
<212> DNA
<213>人工序列
<220>
<221> misc_feature
<223>引物
<400> 68
cacagctggg gtttggtga 19
Claims (10)
1.一种封闭IL6R的用于缓解CRS的CAR-T转基因载体,其特征在于,包括:
用于目的菌株大量扩增的含氨苄青霉素抗性基因AmpR序列,如SEQ ID NO.1所示;
用于质粒复制的原核复制子pUC Ori序列,如SEQ ID NO.2所示;
用于增强真核细胞内的复制的病毒复制子SV40 Ori序列,如SEQ ID NO.3所示;
用于增强转基因的表达效率的eWPRE增强型土拨鼠乙肝病毒转录后调控元件,如SEQID NO.11所示;
用于嵌合抗原受体基因的真核转录的人EF1α启动子,如SEQ ID NO.12所示;
用于慢病毒包装的慢病毒包装顺式元件;
人IL6R的人源化单链抗体,所述人IL6R的人源化单链抗体为如SEQ ID NO.21所示的IL6RscFv1,或者如SEQ ID NO.22所示的IL6RscFv2,或者如SEQ ID NO.23所示的IL6RscFv3;
用于共同转录表达蛋白质的IRES核糖体结合序列,如SEQ ID NO.25所示;
IL6信号肽,如SEQ ID NO.26所示;
人源抗体Fc段,如SEQ ID NO.27所示;
以及用于组成集识别、传递、启动于一体的二代CAR或三代CAR的嵌合抗原受体。
2.如权利要求1所述的载体,其特征在于,所述人IL6R的人源化单链抗体为如SEQ IDNO.21所示的IL6RscFv1。
3.如权利要求1所述的载体,其特征在于,所述慢病毒包装顺式元件采用第二代慢病毒载体包括:如SEQ ID NO.5所示的慢病毒5 terminal LTR、如SEQ ID NO.6所示的慢病毒3terminal Self-Inactivating LTR、如SEQ ID NO.7所示的Gag顺式元件、如SEQ ID NO.8所示的RRE顺式元件、如SEQ ID NO.9所示的env顺式元件、如SEQ ID NO.10所示的cPPT顺式元件。
4.如权利要求1所述的载体,其特征在于,所述慢病毒包装顺式元件采用第三代慢病毒载体包括:如SEQ ID NO.5所示的慢病毒5 terminal LTR、如SEQ ID NO.6所示的慢病毒3terminal Self-Inactivating LTR、如SEQ ID NO.7所示的Gag顺式元件、如SEQ ID NO.8所示的RRE顺式元件、如SEQ ID NO.9所示的env顺式元件、如SEQ ID NO.10所示的cPPT顺式元件,以及如SEQ ID NO.4所示的RSV启动子。
5.如权利要求1所述的载体,其特征在于,所述用于组成集识别、传递、启动于一体的二代CAR的嵌合抗原受体包括:如SEQ ID NO.13所示的CD8 leader嵌合受体信号肽、如SEQ IDNO.14所示的CD19单链抗体轻链VL、如SEQ ID NO.15所示的Optimal Linker C、如SEQ IDNO.16所示的CD19单链抗体重链VH、如SEQ ID NO.17所示的CD8 Hinge嵌合受体铰链、如SEQID NO.18所示的CD8 Transmembrane嵌合受体跨膜区、如SEQ ID NO.19所示的CD137嵌合受体共刺激因子、如SEQ ID NO.20所示的TCR嵌合受体T细胞激活域;
所述用于组成集识别、传递、启动于一体的三代CAR的嵌合抗原受体包括:如SEQ IDNO.13所示的CD8 leader嵌合受体信号肽、如SEQ ID NO.14所示的CD19单链抗体轻链VL、如SEQ ID NO.15所示的Optimal Linker C、如SEQ ID NO.16所示的CD19单链抗体重链VH、如SEQ ID NO.17所示的CD8 Hinge嵌合受体铰链、如SEQ ID NO.18所示的CD8 Transmembrane嵌合受体跨膜区、如SEQ ID NO.19所示的CD137嵌合受体共刺激因子、如SEQ ID NO.20所示的TCR嵌合受体T细胞激活域、以及如SEQ ID NO.28所示的CD28嵌合受体共刺激因子。
6.如权利要求1-5任一项所述的载体,其特征在于,所述eWPRE增强型土拨鼠乙肝病毒转录后调控元件有6个核苷酸的增强突变,具体为:g.396G>A、g.397C>T、g.398T>C、g.399G>A、g.400A>T、g.411A>T。
7.一种如权利要求1-6任一项所述的封闭IL6R的用于缓解CRS的CAR-T转基因载体的构建方法,其特征在于,包括以下步骤:
(1)将如SEQ ID NO.1所示的含氨苄青霉素抗性基因AmpR序列、如SEQ ID NO.2所示的原核复制子pUC Ori序列、如SEQ ID NO.3所示的病毒复制子SV40 Ori序列、用于慢病毒包装的慢病毒包装顺式元件、如SEQ ID NO.11所示的eWPRE增强型土拨鼠乙肝病毒转录后调控元件存储于慢病毒骨架质粒上;
(2)将如SEQ ID NO.12所示的人EF1α启动子、用于组成集识别、传递、启动于一体的二代CAR或三代CAR的嵌合抗原受体组合成二代CAR或三代CAR设计方案,经过酶切、连接、重组反应克隆至慢病毒骨架质粒中,得到二代CAR或三代CAR设计的重组慢病毒质粒;
(3)将人IL6R的人源化单链抗体IL6RscFv1、IL6RscFv2、或IL6RscFv3,IRES核糖体结合序列、IL6信号肽以及人源抗体Fc段分别克隆至重组慢病毒质粒中,得到IL-6R阻断重组慢病毒质粒pCAR19-IL6RscFv1、pCAR19-IL6RscFv2、或pCAR19-IL6RscFv3;
(4)将得到的重组慢病毒质粒pCAR19-IL6RscFv1、pCAR19-IL6RscFv2、或pCAR19-IL6RscFv3分别与慢病毒包装质粒pPac-GP、pPac-R以及膜蛋白质粒pEnv-G共同转染HEK293T/17细胞,在HEK293T/17细胞中进行基因转录表达后,包装成功重组慢病毒载体会释放到细胞培养上清中,收集包含的重组慢病毒载体的上清液;
(5)将得到的重组慢病毒上清采用抽滤、吸附、洗脱的柱纯化方式进行纯化,分别得到重组慢病毒载体。
8.如权利要求7所述的方法,其特征在于,步骤(3)中,由人EF1α启动子启动整个CAR基因表达;CAR蛋白定位于细胞膜表面,识别CD19抗原,刺激T细胞增殖和细胞因子分泌,激活下游信号通路的表达;当scfv区域与CD19抗原结合时,信号通过嵌合受体传递至细胞内,从而产生T细胞增殖、细胞因子分泌增加、抗细胞凋亡蛋白分泌增加、细胞死亡延迟、裂解靶细胞一系列生物学效应;由IRES核糖体结合序列共表达IL6RscFv与Fc的融合蛋白,并在IL6信号肽的引导下分泌到细胞外,通过与IL6R的结合,阻断IL-6的与IL6R的结合,从而阻断IL6的信号通路,达到抑制CRS的效果。
9.如权利要求7所述的方法,其特征在于,步骤(5)中,所述抽滤步骤要控制上清体积在200ml~2000ml,控制真空度在-0.5MPA~-0.9MPA,防止由于堵孔带来的载体损失;所述吸附步骤要控制溶液的PH值在6~8,防止PH的变化导致载体失活;所述洗脱步骤要控制洗脱液的离子强度在0.5M~1.0M,防止离子强度的变化导致洗脱不完全或者载体失活。
10.如权利要求1-6任一项所述的载体在制备缓解CRS的药物中的应用。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611103319.2A CN108148863B (zh) | 2016-12-05 | 2016-12-05 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
PCT/CN2017/110654 WO2018103502A1 (zh) | 2016-12-05 | 2017-11-13 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
US16/464,680 US11066680B2 (en) | 2016-12-05 | 2017-11-13 | IL6R block CAR-T transgenic vector for alleviating CRS, preparation method thereof |
EP17879114.1A EP3550020A4 (en) | 2016-12-05 | 2017-11-13 | TRANSGENIC VECTOR CART-T INVALIDATION OF IL-6R FOR ATTENUATING CRS, ITS METHOD OF PREPARATION AND ITS APPLICATION |
JP2019530056A JP6783009B2 (ja) | 2016-12-05 | 2017-11-13 | Il6rがブロッキングされたcrsを緩和するためのcar−t遺伝子組換えベクターおよびその構築方法と使用 |
KR1020197017090A KR102157196B1 (ko) | 2016-12-05 | 2017-11-13 | 일종의 il6r 차단을 통한 crs 완화에 사용되는 car-t 형질 전환 벡터와 그의 구축방법 및 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611103319.2A CN108148863B (zh) | 2016-12-05 | 2016-12-05 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108148863A true CN108148863A (zh) | 2018-06-12 |
CN108148863B CN108148863B (zh) | 2019-12-17 |
Family
ID=62470631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611103319.2A Active CN108148863B (zh) | 2016-12-05 | 2016-12-05 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11066680B2 (zh) |
EP (1) | EP3550020A4 (zh) |
JP (1) | JP6783009B2 (zh) |
KR (1) | KR102157196B1 (zh) |
CN (1) | CN108148863B (zh) |
WO (1) | WO2018103502A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019076489A1 (en) * | 2017-10-19 | 2019-04-25 | Cellectis | TARGETED GENE INTEGRATION OF CRS INHIBITORY GENES FOR ENHANCED CELL IMMUNOTHERAPY |
CN110846344A (zh) * | 2019-11-18 | 2020-02-28 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种表达il-6r阻断抗体的靶向cd19的嵌合抗原受体t细胞及制备方法、应用 |
CN113677356A (zh) * | 2019-01-07 | 2021-11-19 | 湖南思为康医药有限公司 | 用于降低毒性的共表达嵌合抗原受体和il-6拮抗剂的修饰免疫细胞及其在过继细胞疗法中的用途 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3008162A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
CA2971186A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
RS64053B1 (sr) | 2015-10-30 | 2023-04-28 | Univ California | Polipeptidi koji reaguju na transformišući faktor rasta – beta i postupci za njihovu upotrebu |
CN109963590B (zh) * | 2016-09-02 | 2024-03-15 | 加利福尼亚大学董事会 | 涉及白介素-6受体α结合单链可变片段的方法和组合物 |
CN110055224B (zh) * | 2019-04-03 | 2023-06-30 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
CN110749735A (zh) * | 2019-11-27 | 2020-02-04 | 合肥中科干细胞再生医学有限公司 | 一种示踪剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105602992A (zh) * | 2016-03-17 | 2016-05-25 | 上海优卡迪生物医药科技有限公司 | 一种基于复制缺陷性重组慢病毒的car-t转基因载体及其构建方法和应用 |
CN105814083A (zh) * | 2013-10-15 | 2016-07-27 | 加州生物医学研究所 | 嵌合抗原受体t细胞开关和其用途 |
CN105950662A (zh) * | 2016-05-17 | 2016-09-21 | 上海优卡迪生物医药科技有限公司 | 一种靶向cd22的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE053556T2 (hu) * | 2012-07-13 | 2021-07-28 | Univ Pennsylvania | CAR-ok tumorellenes hatásának toxicitás-menedzsmentje |
CN105640990A (zh) | 2016-01-06 | 2016-06-08 | 奥思达干细胞有限公司 | 一种治疗乳腺癌的car-t细胞制剂及其制备方法 |
CA3018382A1 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
CN105950664B (zh) * | 2016-05-17 | 2019-03-29 | 上海优卡迪生物医药科技有限公司 | 一种靶向cd123的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 |
CN105950663B (zh) * | 2016-05-17 | 2019-04-02 | 上海优卡迪生物医药科技有限公司 | 一种靶向cd30的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 |
CN109963590B (zh) * | 2016-09-02 | 2024-03-15 | 加利福尼亚大学董事会 | 涉及白介素-6受体α结合单链可变片段的方法和组合物 |
CN106636090B (zh) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
CN107245500B (zh) * | 2017-05-27 | 2019-05-17 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用 |
-
2016
- 2016-12-05 CN CN201611103319.2A patent/CN108148863B/zh active Active
-
2017
- 2017-11-13 WO PCT/CN2017/110654 patent/WO2018103502A1/zh unknown
- 2017-11-13 US US16/464,680 patent/US11066680B2/en active Active
- 2017-11-13 EP EP17879114.1A patent/EP3550020A4/en active Pending
- 2017-11-13 JP JP2019530056A patent/JP6783009B2/ja active Active
- 2017-11-13 KR KR1020197017090A patent/KR102157196B1/ko active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105814083A (zh) * | 2013-10-15 | 2016-07-27 | 加州生物医学研究所 | 嵌合抗原受体t细胞开关和其用途 |
CN105602992A (zh) * | 2016-03-17 | 2016-05-25 | 上海优卡迪生物医药科技有限公司 | 一种基于复制缺陷性重组慢病毒的car-t转基因载体及其构建方法和应用 |
CN105950662A (zh) * | 2016-05-17 | 2016-09-21 | 上海优卡迪生物医药科技有限公司 | 一种靶向cd22的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 |
Non-Patent Citations (3)
Title |
---|
FANG CHEN等: "Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy", 《J IMMUNOL METHODS.》 * |
YELEI GUO 等: "Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects", 《JOURNAL OF IMMUNOLOGY RESEARCH》 * |
王蕾 等: "嵌合抗原受体修饰的CAR-T/NK细胞在多发性骨髓瘤治疗中的应用", 《中国实验血液学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019076489A1 (en) * | 2017-10-19 | 2019-04-25 | Cellectis | TARGETED GENE INTEGRATION OF CRS INHIBITORY GENES FOR ENHANCED CELL IMMUNOTHERAPY |
CN113677356A (zh) * | 2019-01-07 | 2021-11-19 | 湖南思为康医药有限公司 | 用于降低毒性的共表达嵌合抗原受体和il-6拮抗剂的修饰免疫细胞及其在过继细胞疗法中的用途 |
CN110846344A (zh) * | 2019-11-18 | 2020-02-28 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种表达il-6r阻断抗体的靶向cd19的嵌合抗原受体t细胞及制备方法、应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3550020A1 (en) | 2019-10-09 |
JP2019535302A (ja) | 2019-12-12 |
US11066680B2 (en) | 2021-07-20 |
KR20190072672A (ko) | 2019-06-25 |
EP3550020A4 (en) | 2019-12-04 |
WO2018103502A1 (zh) | 2018-06-14 |
CN108148863B (zh) | 2019-12-17 |
JP6783009B2 (ja) | 2020-11-11 |
US20190292564A1 (en) | 2019-09-26 |
KR102157196B1 (ko) | 2020-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107058315B (zh) | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 | |
CN108148862B (zh) | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 | |
CN108148863B (zh) | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 | |
CN107245500B (zh) | 一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用 | |
KR102266755B1 (ko) | 인간 인터류킨 6의 siRNA, 재조합 발현 CAR-T 벡터 및 그의 제조 방법 및 용도 | |
CN107325185B (zh) | 基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体 | |
CN108018312B (zh) | 一种t淋巴细胞白血病的car-t治疗载体及其构建方法和应用 | |
CN107337736B (zh) | Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用 | |
CN107287207B (zh) | 一种用于体内示踪和人工清除car-t细胞的标签和应用 | |
CN107267555B (zh) | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 | |
CN112673092B (zh) | 工程化的免疫刺激性细菌菌株及其用途 | |
CN107299110B (zh) | 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用 | |
KR20170108946A (ko) | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 | |
CN112111462B (zh) | 烯醇化酶eno1单克隆抗体及其应用 | |
CN107058232B (zh) | 胆固醇转脂酶soat1被抑制的car‑t细胞及其制备方法和应用 | |
CN110218250A (zh) | 一种草鱼补体成分5多克隆抗体的制备方法 | |
WO2020169221A1 (en) | Production of plant-based active substances (e.g. cannabinoids) by recombinant microorganisms | |
CN107164410B (zh) | 一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用 | |
CN107177632B (zh) | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 | |
CN108456662B (zh) | 针对肝癌相关抗原dlk1为靶点的car-t构建方法 | |
CN107326089A (zh) | 一种基于NGS检测Septin9基因启动子甲基化的方法及其应用 | |
CN108660111A (zh) | Car-cik转基因细胞及其制备方法和应用 | |
CN114805578B (zh) | 一种白细胞免疫球蛋白样受体亚家族b成员2的羊驼纳米抗体、制备方法及其应用 | |
Barbet et al. | Shared surface epitopes among trypanosomes of the same serodeme expressing different variable surface glycoprotein genes | |
RU2779747C2 (ru) | Химерные антигенные рецепторы, нацеленные на подобный fc-рецептору белок 5, и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |